Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1
value | Author stringclasses 1
value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
38300.0 | 2019-07-10 00:00:00 UTC | Aurora Cannabis: 3 High-Risk, High-Reward Acquisitions to Consider | ACB | https://www.nasdaq.com/articles/aurora-cannabis%3A-3-high-risk-high-reward-acquisitions-to-consider-2019-07-10 | nan | nan | According to online investing app Robinhood, there isn't a more popular stock on the planet than Aurora Cannabis (NYSE: ACB). Data from the investing app that caters to 6 million investors, most of whom are millennials, shows that Aurora is the most-held stock, period! That makes it more popular than Facebook, Amazon.c... | According to online investing app Robinhood, there isn't a more popular stock on the planet than Aurora Cannabis (NYSE: ACB). Aurora isn't afraid to pay hefty premiums to expand its reach, meaning it's probably more willing to take high risks with acquisitions if the potential reward is also great. Even though not all ... | According to online investing app Robinhood, there isn't a more popular stock on the planet than Aurora Cannabis (NYSE: ACB). Here's why retail investors love Aurora Cannabis There are a number of factors that attract investors to Aurora Cannabis, with its production capacity, international reach, and focus on the medi... | According to online investing app Robinhood, there isn't a more popular stock on the planet than Aurora Cannabis (NYSE: ACB). Here's why retail investors love Aurora Cannabis There are a number of factors that attract investors to Aurora Cannabis, with its production capacity, international reach, and focus on the medi... | According to online investing app Robinhood, there isn't a more popular stock on the planet than Aurora Cannabis (NYSE: ACB). Here's why retail investors love Aurora Cannabis There are a number of factors that attract investors to Aurora Cannabis, with its production capacity, international reach, and focus on the medi... |
38301.0 | 2019-07-10 00:00:00 UTC | Improving Cannabis Market Fundamentals Make Aurora Stock a Buy | ACB | https://www.nasdaq.com/articles/improving-cannabis-market-fundamentals-make-aurora-stock-a-buy-2019-07-10 | nan | nan | Shares of Canadian cannabis giant Aurora (NYSE:) have been on a roller-coaster ride in 2019. Year to date, ACB stock is up more than 50%. Ostensibly, that’s a huge rally. But that metric itself misses the full picture. Back in late March, ACB stock was up a whopping 90% year-to-date. Thus, since then, Aurora stock has ... | Third, Aurora’s long-term profit growth potential as an important player in a huge market is not priced into ACB stock today. Year to date, ACB stock is up more than 50%. Back in late March, ACB stock was up a whopping 90% year-to-date. | Third, Aurora’s long-term profit growth potential as an important player in a huge market is not priced into ACB stock today. Aurora Stock Is Arguably Undervalued Third, given its reasonable outlook as an important player in the $200 billion global cannabis market, Aurora has tremendous long-term profit growth potentia... | As such, ACB stock has bounced around over the past few months as investors have struggled to understand: 1) just how big the cannabis market will be, and 2) how important of a player Aurora will be in that market at scale. Aurora Stock Is Arguably Undervalued Third, given its reasonable outlook as an important player ... | Aurora Stock Is Arguably Undervalued Third, given its reasonable outlook as an important player in the $200 billion global cannabis market, Aurora has tremendous long-term profit growth potential, only a fraction of which is priced into ACB stock today. Year to date, ACB stock is up more than 50%. Back in late March, A... |
38302.0 | 2019-07-09 00:00:00 UTC | Analysts Say the Dilution of Aurora Cannabis Stock Will Eventually Be Worth It | ACB | https://www.nasdaq.com/articles/analysts-say-the-dilution-of-aurora-cannabis-stock-will-eventually-be-worth-it-2019-07-09 | nan | nan | Aurora Cannabis (NYSE:) is already Canada’s biggest cannabis grower, and has set the stage to become one of the world’s biggest by around this time next year. But on the other hand, ACB stock has made absolutely no progress since the end of 2017.
Granted, it’s not the only marijuana stock that’s struggled to gain trac... | For instance, late last year it shelled out nearly $300 million worth of ACB stock to acquire Latin American outfit ICC Labs. Can the company start to show signs of enough life within the next few quarters to justify the dilution ACB stock owners are being forced to digest? But on the other hand, ACB stock has made abs... | The opposing expectations are making Aurora Cannabis stock tough to trade, and ACB stock will likely remain erratic until it’s clear Aurora can turn a meaningful profit or clearly can’t. But on the other hand, ACB stock has made absolutely no progress since the end of 2017. ACB stock, however, has been particularly dis... | Still, ACB is moving in a generally positive direction, and that should be positive for Aurora stock. The opposing expectations are making Aurora Cannabis stock tough to trade, and ACB stock will likely remain erratic until it’s clear Aurora can turn a meaningful profit or clearly can’t. But on the other hand, ACB stoc... | The opposing expectations are making Aurora Cannabis stock tough to trade, and ACB stock will likely remain erratic until it’s clear Aurora can turn a meaningful profit or clearly can’t. But on the other hand, ACB stock has made absolutely no progress since the end of 2017. ACB stock, however, has been particularly dis... |
38303.0 | 2019-07-09 00:00:00 UTC | 10 Stocks to Buy on College Students’ Radars | ACB | https://www.nasdaq.com/articles/10-stocks-to-buy-on-college-students-radars-2019-07-09 | nan | nan | College represents a life-changing experience for many reasons. Primarily, higher education provides students with the credentials necessary to spark hopefully fruitful and satisfying careers. However, it also provides a trial period toward adulthood. This can include planning financially for the future with lucrative ... | So with that, here are my top 10 stocks to buy for college-aged buyers: Aurora Cannabis (ACB) Peruse InvestorPlace’s listing of popular stocks to buy, and you’ll invariably come across green investments. Recently, this industry has suffered due to generally disappointing earnings performances, and ACB stock was no diff... | So with that, here are my top 10 stocks to buy for college-aged buyers: Aurora Cannabis (ACB) Peruse InvestorPlace’s listing of popular stocks to buy, and you’ll invariably come across green investments. Recently, this industry has suffered due to generally disappointing earnings performances, and ACB stock was no diff... | So with that, here are my top 10 stocks to buy for college-aged buyers: Aurora Cannabis (ACB) Peruse InvestorPlace’s listing of popular stocks to buy, and you’ll invariably come across green investments. Recently, this industry has suffered due to generally disappointing earnings performances, and ACB stock was no diff... | So with that, here are my top 10 stocks to buy for college-aged buyers: Aurora Cannabis (ACB) Peruse InvestorPlace’s listing of popular stocks to buy, and you’ll invariably come across green investments. Recently, this industry has suffered due to generally disappointing earnings performances, and ACB stock was no diff... |
38304.0 | 2019-07-08 00:00:00 UTC | After Hours: Marijuana Stock ETF to Start Trading, Chipotle Cruises to a New High | ACB | https://www.nasdaq.com/articles/after-hours%3A-marijuana-stock-etf-to-start-trading-chipotle-cruises-to-a-new-high-2019-07 | nan | nan | In contrast to a memorable Monday for stocks, tonight's after-market action is relatively subdued. There haven't been too many earth-shaking news items rattling share prices; for the most part, traders seem to be taking the night off.
Tomorrow might be a different story, since there's a new security on the marijuana st... | Stocks within the ETF at launch will include the famous names in the sector and companies associated with it, such as Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), and Scotts Miracle-Gro. The securities that comprise this marijuana stock ETF will mirror the 36 listed on the company's Innovation Labs Cannabis ... | Stocks within the ETF at launch will include the famous names in the sector and companies associated with it, such as Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), and Scotts Miracle-Gro. The Cannabis ETF, a rather bluntly named security from an ETF sponsor company called Innovation Shares, will become availa... | Stocks within the ETF at launch will include the famous names in the sector and companies associated with it, such as Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), and Scotts Miracle-Gro. The Cannabis ETF, a rather bluntly named security from an ETF sponsor company called Innovation Shares, will become availa... | Stocks within the ETF at launch will include the famous names in the sector and companies associated with it, such as Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), and Scotts Miracle-Gro. The Cannabis ETF, a rather bluntly named security from an ETF sponsor company called Innovation Shares, will become availa... |
38305.0 | 2019-07-07 00:00:00 UTC | Why Aurora Cannabis Could Become the King of Hemp CBD | ACB | https://www.nasdaq.com/articles/why-aurora-cannabis-could-become-the-king-of-hemp-cbd-2019-07-07 | nan | nan | Canopy Growth made waves with the announcement in January that it's building a large-scale hemp production facility in New York State. The company expects to have hemp cannabidiol (CBD) products on the market by the end of this year. Tilray jumped head first into the hemp market soon after Canopy's announcement with it... | But what about Aurora Cannabis (NYSE: ACB)? Canopy Growth made waves with the announcement in January that it's building a large-scale hemp production facility in New York State. Chief Corporate Officer Cam Battley noted, though, that Aurora is exploring opportunities in the global hemp market with advisor Nelson Peltz... | But what about Aurora Cannabis (NYSE: ACB)? At the same time, Aurora acquired Agropro's sister company Borela, which processes and distributes organic hulled hemp seeds, hemp seed protein, hemp flour, and hemp seed oil. While Aurora has built up an impressive hemp presence in Canada, Europe, and South America, the comp... | But what about Aurora Cannabis (NYSE: ACB)? At the same time, Aurora acquired Agropro's sister company Borela, which processes and distributes organic hulled hemp seeds, hemp seed protein, hemp flour, and hemp seed oil. While Aurora has built up an impressive hemp presence in Canada, Europe, and South America, the comp... | But what about Aurora Cannabis (NYSE: ACB)? Hempco also supplied Aurora with raw hemp for extracting CBD. While Aurora has built up an impressive hemp presence in Canada, Europe, and South America, the company hasn't made any major moves into the biggest hemp CBD market of all: the U.S. |
38306.0 | 2019-07-05 00:00:00 UTC | 3 Marijuana Stocks to Buy Now | ACB | https://www.nasdaq.com/articles/3-marijuana-stocks-to-buy-now-2019-07-05 | nan | nan | For investors solely interested in making profits in marijuana stocks and not enduring investments, it’s a time to look away from the hype and toward the price charts of Aurora Cannabis (NYSE:), Tilray (NASDAQ:) and Innovative Industrial Properties (NYSE:).
What else can be added to the conversation about marijuana sto... | Aurora Cannabis (ACB) Aurora Cannabis is the first of our marijuana stocks to put on the radar for purchase. As the monthly chart shows, ACB stock has been consolidating in a volatile congestion pattern for the past 1.5 years. Last month ACB stock put together a higher low doji candlestick within its volatile uptrend. | Trading ACB Stock My recommendation is to buy ACB stock above the doji high of $8.16. Aurora Cannabis (ACB) Aurora Cannabis is the first of our marijuana stocks to put on the radar for purchase. As the monthly chart shows, ACB stock has been consolidating in a volatile congestion pattern for the past 1.5 years. | Trading ACB Stock My recommendation is to buy ACB stock above the doji high of $8.16. Aurora Cannabis (ACB) Aurora Cannabis is the first of our marijuana stocks to put on the radar for purchase. As the monthly chart shows, ACB stock has been consolidating in a volatile congestion pattern for the past 1.5 years. | Aurora Cannabis (ACB) Aurora Cannabis is the first of our marijuana stocks to put on the radar for purchase. As the monthly chart shows, ACB stock has been consolidating in a volatile congestion pattern for the past 1.5 years. Last month ACB stock put together a higher low doji candlestick within its volatile uptrend. |
38307.0 | 2019-07-05 00:00:00 UTC | Is Aurora Cannabis Stock an Awesome Marijuana Name or Just Average? | ACB | https://www.nasdaq.com/articles/is-aurora-cannabis-stock-an-awesome-marijuana-name-or-just-average | nan | nan | Marijuana stocks, even the marquee players trading on major U.S. exchanges, often move in fits and starts. Aurora Cannabis (NYSE:ACB) is the epitome of a marijuana stock that both tantalizes and vexes investors.
Undoubtedly, a year-to-date gain of nearly 55% is impressive, but looking below the surface, investors will ... | Speaking of profits, seemingly the holy grail of the cannabis space, there is some potentially good news on that front for ACB stock. Aurora Cannabis (NYSE:ACB) is the epitome of a marijuana stock that both tantalizes and vexes investors. Undoubtedly, a year-to-date gain of nearly 55% is impressive, but looking below t... | The Bottom Line on ACB Stock As is the case with many marijuana stocks, on Aurora stock, with the prevailing wisdom on it seeming to be “plenty of potential, but not necessarily a near-term buy.” However, there is risk in adopting that view. Aurora Cannabis (NYSE:ACB) is the epitome of a marijuana stock that both tant... | Azer explained why she thinks Aurora Cannabis stock should command a premium over its rivals, citing what she sees as “its near term path to profitability in conjunction with strong early-stage execution within the nascent Canadian cannabis adult use markets.” Cannabis Catalysts Of course, ACB stock needs catalysts to ... | Aurora Cannabis (NYSE:ACB) is the epitome of a marijuana stock that both tantalizes and vexes investors. Undoubtedly, a year-to-date gain of nearly 55% is impressive, but looking below the surface, investors will also find that ACB stock resides nearly 40% below its 52-week high. Speaking of profits, seemingly the holy... |
38308.0 | 2019-07-05 00:00:00 UTC | Aurora Cannabis Is Spending For Massive Growth On The If-Come | ACB | https://www.nasdaq.com/articles/aurora-cannabis-is-spending-for-massive-growth-on-the-if-come-2019-07-05 | nan | nan | Marijuana was one of the hot investment niches of 2018. In 2019 pot stocks are a battlefield. Aurora Cannabis (NYSE:) is a good example: Since January it’s up over $2 per share, or 54%, but those gains have pared some 23% since ACB stock hit a high in March.
Pot stocks are volatile, subject to quick manias and deep dep... | Aurora Cannabis (NYSE:) is a good example: Since January it’s up over $2 per share, or 54%, but those gains have pared some 23% since ACB stock hit a high in March. Guess What’s Coming For the June quarter, due to be reported August 13, analysts are expecting Aurora to come close to break-even, a loss of 2 cents per sh... | Guess What’s Coming For the June quarter, due to be reported August 13, analysts are expecting Aurora to come close to break-even, a loss of 2 cents per share of ACB stock on revenue of $86 million. Bottom Line on ACB Stock It’s impossible to be certain about how ACB stock, or any pot stock, will do in the future. Auro... | Guess What’s Coming For the June quarter, due to be reported August 13, analysts are expecting Aurora to come close to break-even, a loss of 2 cents per share of ACB stock on revenue of $86 million. Bottom Line on ACB Stock It’s impossible to be certain about how ACB stock, or any pot stock, will do in the future. Auro... | Aurora Cannabis (NYSE:) is a good example: Since January it’s up over $2 per share, or 54%, but those gains have pared some 23% since ACB stock hit a high in March. Guess What’s Coming For the June quarter, due to be reported August 13, analysts are expecting Aurora to come close to break-even, a loss of 2 cents per sh... |
38309.0 | 2019-07-05 00:00:00 UTC | The 5 Big Reasons to Stick with Canopy Stock | ACB | https://www.nasdaq.com/articles/the-5-big-reasons-to-stick-with-canopy-stock-2019-07-05 | nan | nan | Shares of Canadian cannabis leader Canopy Growth (NYSE:) have had a really strong 2019 so far for two big reasons. First, the global cannabis market has demonstrated upward progress through continued strong sales momentum and important legal developments. These factors imply a multi-hundred-billion-dollar market one da... | As of this writing, Luke Lango was long CGC and ACB. First, the global cannabis market has demonstrated upward progress through continued strong sales momentum and important legal developments. They’ve also made strategic acquisitions and investments to similarly dominate the U.S. cannabis market (once it’s fully legal... | As of this writing, Luke Lango was long CGC and ACB. Canopy Growth Stock Projects as the Leader in a Burgeoning Market Second, Canopy Growth projects as the leader in that $200 billion global cannabis market. Long-Term Fundamentals Support the Present Valuation Assuming Canopy becomes the leader of the $200 billion can... | As of this writing, Luke Lango was long CGC and ACB. Canopy Growth Stock Projects as the Leader in a Burgeoning Market Second, Canopy Growth projects as the leader in that $200 billion global cannabis market. Long-Term Fundamentals Support the Present Valuation Assuming Canopy becomes the leader of the $200 billion can... | As of this writing, Luke Lango was long CGC and ACB. Long-Term Fundamentals Support the Present Valuation Assuming Canopy becomes the leader of the $200 billion cannabis market in 10 to 15 years, then CGC stock is presently undervalued relative to its long-term profit growth potential. Strong Technical Support at $40 f... |
38310.0 | 2019-07-03 00:00:00 UTC | Aphria Stock Could Become Cheap Soon | ACB | https://www.nasdaq.com/articles/aphria-stock-could-become-cheap-soon-2019-07-03 | nan | nan | Aphria (NYSE:) stock hasn’t moved much over the last two months. As Aphria stock works to recover from last year’s implosion, analysts’ estimates for APHA are falling even though it landed a lucrative vaping deal. Although Aphria Inc still has not fully regained the confidence of investors, strong production numbers an... | As Aphria stock works to recover from last year’s implosion, analysts’ estimates for APHA are falling even though it landed a lucrative vaping deal. The equity lost more than 75% of its value over three months last year as a Aphria Inc. a “shell game with a cannabis business on the side.” Many expressed doubts about th... | As Aphria stock works to recover from last year’s implosion, analysts’ estimates for APHA are falling even though it landed a lucrative vaping deal. Aphria Stock Will Benefit From Higher Production Levels, Vapes The collapse of APHA stock occurred despite the fact that Aphria Inc. became the in Canada, lagging only Aur... | Aphria Stock Will Benefit From Higher Production Levels, Vapes The collapse of APHA stock occurred despite the fact that Aphria Inc. became the in Canada, lagging only Aurora Cannabis (NYSE:) and Canopy. Aphria Stock Held Back by Uncertainty However, I think two factors will hold back Aphria stock. Final Thoughts on Ap... | As Aphria stock works to recover from last year’s implosion, analysts’ estimates for APHA are falling even though it landed a lucrative vaping deal. Perhaps if the company could install a more permanent leadership team and somehow prevent earnings estimates for it from falling further, Aphria stock would reach its 52-w... |
38311.0 | 2019-07-03 00:00:00 UTC | Where Will Aurora Cannabis Be in 5 Years? | ACB | https://www.nasdaq.com/articles/where-will-aurora-cannabis-be-in-5-years-2019-07-03 | nan | nan | Most Canadian cannabis stocks are seemingly expensive today. After all, virtually none are profitable, and most have quarterly revenue under 100 million Canadian dollars. Yet some of these companies have seen their stocks bid up into the multibillions in market capitalization. In fact, Canadian leader Aurora Cannabis (... | In fact, Canadian leader Aurora Cannabis (NYSE: ACB) is currently valued at roughly $8 billion, despite making only about CA$75 million in revenue in its most recent quarter. Polaris will focus on manufacturing cannabis from flower produced at the adjacent Aurora Sky facility into edibles, vapes, soft gels, and cosmeti... | In fact, Canadian leader Aurora Cannabis (NYSE: ACB) is currently valued at roughly $8 billion, despite making only about CA$75 million in revenue in its most recent quarter. When current and funded capacity comes online, Aurora will be capable of producing over 625,000 kilos of cannabis annually -- roughly 10 times th... | In fact, Canadian leader Aurora Cannabis (NYSE: ACB) is currently valued at roughly $8 billion, despite making only about CA$75 million in revenue in its most recent quarter. Aurora's management believes it can drive down costs to "well below CA$1 per gram," as its main Aurora Sky facility ramps up production this year... | In fact, Canadian leader Aurora Cannabis (NYSE: ACB) is currently valued at roughly $8 billion, despite making only about CA$75 million in revenue in its most recent quarter. The first quarter also saw an inflection in the company's growing capabilities, with production surging nearly 100% quarter over quarter, not yea... |
38312.0 | 2019-07-03 00:00:00 UTC | A $1,000 Investment in Aurora, Canopy, Cronos, and HEXO at the Beginning of 2019 Is Worth This Much Today | ACB | https://www.nasdaq.com/articles/a-%241000-investment-in-aurora-canopy-cronos-and-hexo-at-the-beginning-of-2019-is-worth-this | nan | nan | Marijuana stocks have undergone a striking change so far in 2019. In the first quarter, it was game on for investors, with 14 cannabis stocks gaining more than 70%, and the Horizons Marijuana Life Sciences ETF galloping forward by about 50%. The prospect of rapid sales growth and the impending launch of derivative pot ... | Here's how you fared if you bought the most popular pot stocks But when discussing the state of the cannabis industry, what investors really want to know is how the four most popular pot stocks are performing: Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), Cronos Group (NASDAQ: CRON), and HEXO (NYSEMKT: HEXO).... | Here's how you fared if you bought the most popular pot stocks But when discussing the state of the cannabis industry, what investors really want to know is how the four most popular pot stocks are performing: Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), Cronos Group (NASDAQ: CRON), and HEXO (NYSEMKT: HEXO).... | Here's how you fared if you bought the most popular pot stocks But when discussing the state of the cannabis industry, what investors really want to know is how the four most popular pot stocks are performing: Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), Cronos Group (NASDAQ: CRON), and HEXO (NYSEMKT: HEXO).... | Here's how you fared if you bought the most popular pot stocks But when discussing the state of the cannabis industry, what investors really want to know is how the four most popular pot stocks are performing: Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), Cronos Group (NASDAQ: CRON), and HEXO (NYSEMKT: HEXO).... |
38313.0 | 2019-07-02 00:00:00 UTC | Global Legalization Will Determine the Fate of Aurora Stock | ACB | https://www.nasdaq.com/articles/global-legalization-will-determine-the-fate-of-aurora-stock-2019-07-02 | nan | nan | Among the major cannabis plays, Canada’s Aurora Cannabis (NYSE:) has mostly gone its own way. Rivals Canopy Growth (NYSE:) and Cronos (NASDAQ:) have sold billions of dollars’ worth of stock for cash to fund their growth. Aurora, instead, has used ACB stock to buy smaller companies. It has issued over 1 billion shares o... | As we have seen in U.S. markets like Oregon and Colorado, that leads to , thin margins, and likely a lower ACB stock price. Aurora, instead, has used ACB stock to buy smaller companies. The steady issuance of ACB stock has diluted shareholders. | Aurora, instead, has used ACB stock to buy smaller companies. The steady issuance of ACB stock has diluted shareholders. The Market Risk to ACB Stock It would seem like producers have several markets in which to sell cannabis as possession of marijuana is legalized or decriminalized in areas around the world. | The Market Risk to ACB Stock It would seem like producers have several markets in which to sell cannabis as possession of marijuana is legalized or decriminalized in areas around the world. Aurora, instead, has used ACB stock to buy smaller companies. The steady issuance of ACB stock has diluted shareholders. | Aurora, instead, has used ACB stock to buy smaller companies. The Market Risk to ACB Stock It would seem like producers have several markets in which to sell cannabis as possession of marijuana is legalized or decriminalized in areas around the world. The steady issuance of ACB stock has diluted shareholders. |
38314.0 | 2019-07-02 00:00:00 UTC | 3 Things Limiting Aurora Cannabis' Upside | ACB | https://www.nasdaq.com/articles/3-things-limiting-aurora-cannabis-upside-2019-07-02 | nan | nan | The marijuana industry is expected to see up to $75 billion in global (legal) sales by 2030, and it has dozens upon dozens of pot stocks for investors to choose from. But when it comes to popularity, no marijuana stock is more actively held by investors than Aurora Cannabis (NYSE: ACB).
Investors love pot stocks, and A... | But when it comes to popularity, no marijuana stock is more actively held by investors than Aurora Cannabis (NYSE: ACB). In other words, focusing on medical marijuana patients is Aurora's means of bolstering its margins, in addition to recognizing economies of scale as its larger grow operations come on line. Though th... | But when it comes to popularity, no marijuana stock is more actively held by investors than Aurora Cannabis (NYSE: ACB). Investors love pot stocks, and Aurora is at the top of their list Aurora Cannabis projects as the largest Canadian marijuana producer by peak output. In just the past 19 quarters (4 3/4 years), Auror... | But when it comes to popularity, no marijuana stock is more actively held by investors than Aurora Cannabis (NYSE: ACB). Investors love pot stocks, and Aurora is at the top of their list Aurora Cannabis projects as the largest Canadian marijuana producer by peak output. Since August 2016, Aurora Cannabis has made 15 ac... | But when it comes to popularity, no marijuana stock is more actively held by investors than Aurora Cannabis (NYSE: ACB). Investors love pot stocks, and Aurora is at the top of their list Aurora Cannabis projects as the largest Canadian marijuana producer by peak output. The company simply cannot issue 1 billion shares ... |
38315.0 | 2019-07-02 00:00:00 UTC | 3 Reasons Cronos Group Stock Deserves A Buy Rating | ACB | https://www.nasdaq.com/articles/3-reasons-cronos-group-stock-deserves-a-buy-rating-2019-07-02 | nan | nan | Last month, Bank of America analyst Christopher Carey upgraded Cronos Group (NASDAQ:) from an underperform rating to a buy, sending CRON stock 11% higher on the news.
Source: Shutterstock
Since Carey’s June 4 of Cronos stock, it’s gone sideways, finishing the month of June at $15.98, a penny less than where it traded ... | Last month, Bank of America analyst Christopher Carey upgraded Cronos Group (NASDAQ:) from an underperform rating to a buy, sending CRON stock 11% higher on the news. Having this kind of access to quality concentrates will help it keep on top of demand once products are legally available in December and into 2020 Also,... | Last month, Bank of America analyst Christopher Carey upgraded Cronos Group (NASDAQ:) from an underperform rating to a buy, sending CRON stock 11% higher on the news. In previous articles, I’ve suggested that Cronos Group stock, along with Canopy Growth (NYSE:) and Hexo (NYSEAMERICAN:HEXO) are the three best Canadian c... | Last month, Bank of America analyst Christopher Carey upgraded Cronos Group (NASDAQ:) from an underperform rating to a buy, sending CRON stock 11% higher on the news. Well, the day last December that Altria (NYSE:) announced that it would invest $1.8 billion in Cronos for 45% of the company with an option to buy anothe... | In previous articles, I’ve suggested that Cronos Group stock, along with Canopy Growth (NYSE:) and Hexo (NYSEAMERICAN:HEXO) are the three best Canadian cannabis investments. It’s trading at less than three times cash. Working closely with MediPharm, Cronos ought to be able to capture a chunk of the Canadian derivatives... |
38316.0 | 2019-07-01 00:00:00 UTC | ACB Stock Could See Future Growth on Cannabis Edibles Bet | ACB | https://www.nasdaq.com/articles/acb-stock-could-see-future-growth-on-cannabis-edibles-bet-2019-07-01 | nan | nan | Aurora Cannabis (NYSE:) is hitting its production stride, eight months into the legalization of recreational marijuana in Canada. ACB stock has dropped from its peak when Canada made pot legal as the reality of the situation has hit investors. There was no mad (or at least sustained) stampede to cannabis stores, and in... | ACB stock has dropped from its peak when Canada made pot legal as the reality of the situation has hit investors. That is expected to be the next wave of growth for cannabis stocks like ACB stock — at least if the companies are prepared for the new opportunity. Aurora Stockpiling Could Boost ACB Stock Later Given the h... | ACB stock has dropped from its peak when Canada made pot legal as the reality of the situation has hit investors. That is expected to be the next wave of growth for cannabis stocks like ACB stock — at least if the companies are prepared for the new opportunity. Aurora Stockpiling Could Boost ACB Stock Later Given the h... | Aurora Stockpiling Could Boost ACB Stock Later Given the high value potential of the cannabis edibles market, it’s not surprising to learn that the big cannabis companies are making their moves to grab as much of it as possible. ACB stock has dropped from its peak when Canada made pot legal as the reality of the situat... | ACB stock has dropped from its peak when Canada made pot legal as the reality of the situation has hit investors. That is expected to be the next wave of growth for cannabis stocks like ACB stock — at least if the companies are prepared for the new opportunity. Aurora Stockpiling Could Boost ACB Stock Later Given the h... |
38317.0 | 2019-07-01 00:00:00 UTC | Canopy Growth Stock: Should CGC Investors Err on the Side of Caution? | ACB | https://www.nasdaq.com/articles/canopy-growth-stock%3A-should-cgc-investors-err-on-the-side-of-caution-2019-07-01 | nan | nan | Investors in the cannabis sector are well aware of how volatile the stock price of Canada-based Canopy Growth (NYSE:) and its peers can be. They were not impressed with CGC’s fourth-quarter results for the three months ended March 31, 2019, as shares dipped below $40 following the report’s release in June.
Source:
Now ... | Although it is too soon to predict how the legal hemp production in the U.S. will affect CGC stock’s bottom line, analysts believe the partnership between Canopy Growth and Constellation Brands is the area to watch. It is important to underline that none of the Canadian cannabis stocks have done any business in these p... | CGC stock’s main competitors include Aurora Cannabis (NYSE:), Tilray (NASDAQ:) and Cronos Group (NASDAQ:), all Canada-based companies. If there is any broader market weakness in Canadian stocks, say due to market worries over U.S.-China trade wars, Canopy Growth share price may be further adversely affected. The follow... | Source: Now that the CGC earnings season is behind us, let’s look at what may be next for Canopy Growth stock, particularly within the context of marijuana legalization in Canada and the U.S. Canada Was the First G7 Nation to Legalize Marijuana Canada stepped into the spotlight in 2018 when it passed the and became the... | In 2019, the total cannabis market in Canada, including both legal and illegal recreational and medical sales, is expected to be around . If the trend continues, then the market expects Canopy Growth stock’s sales to increase further. Sales to the Canadian recreational cannabis market generate most of CGC’s growth. |
38318.0 | 2019-07-01 00:00:00 UTC | Can Vaping Growth Help Investors Extract More Value From Aphria Stock? | ACB | https://www.nasdaq.com/articles/can-vaping-growth-help-investors-extract-more-value-from-aphria-stock-2019-07-01 | nan | nan | Of the multiple positive catalysts should fuel Aphria Inc (NYSE:) in the months ahead, the most intriguing one is is vaping, or using a vaporizer to get the desired effect from cannabis use. My InvestorPlace colleague Will Healy pointed out some of these catalysts in his June 6 article, when APHA stock was trading at m... | Of the multiple positive catalysts should fuel Aphria Inc (NYSE:) in the months ahead, the most intriguing one is is vaping, or using a vaporizer to get the desired effect from cannabis use. Source: Shutterstock The next day, Aphria that it had entered into a supply agreement for the Canadian market with San Francisco-... | Of the multiple positive catalysts should fuel Aphria Inc (NYSE:) in the months ahead, the most intriguing one is is vaping, or using a vaporizer to get the desired effect from cannabis use. “As Aphria continues to drive the evolution of the industry, we are thrilled to partner with a technology leader like PAX to prov... | “As Aphria continues to drive the evolution of the industry, we are thrilled to partner with a technology leader like PAX to provide a new avenue for consumers to integrate cannabis into their lives,” said Irwin Simon, interim CEO of Aphria. “We are excited to bring our premium cannabis extracts from Solei, RIFF and ou... | In the U.S. alone, Pax has sold more than 500,000 Era vaporizers to date with plenty of growth expected in the months and years ahead. “As Aphria continues to drive the evolution of the industry, we are thrilled to partner with a technology leader like PAX to provide a new avenue for consumers to integrate cannabis int... |
38319.0 | 2019-06-30 00:00:00 UTC | The 10 Fastest-Growing Pot Stocks in 2020 | ACB | https://www.nasdaq.com/articles/the-10-fastest-growing-pot-stocks-in-2020-2019-06-30 | nan | nan | In case you haven't heard, the marijuana industry is forecast to grow at one of the fastest paces of any industry in the world. A newly released report, "State of the Legal Cannabis Markets," from Arcview Market Research and BDS Analytics, forecasts a near-quadrupling in global licensed-store sales in the six-year peri... | Aurora Cannabis: 171% YOY sales growth No surprise here, either: The largest cannabis producer in the world, Aurora Cannabis (NYSE: ACB), should be one of the 10 fastest-growing pot stocks next year. Unlike most growers, which are expected to flood the market with discount or average-quality cannabis, Flowr is using ge... | Aurora Cannabis: 171% YOY sales growth No surprise here, either: The largest cannabis producer in the world, Aurora Cannabis (NYSE: ACB), should be one of the 10 fastest-growing pot stocks next year. Canopy Growth: 234% YOY sales growth Not surprisingly, the largest pot stock in the world and the company slated to prod... | Aurora Cannabis: 171% YOY sales growth No surprise here, either: The largest cannabis producer in the world, Aurora Cannabis (NYSE: ACB), should be one of the 10 fastest-growing pot stocks next year. Auxly Cannabis Group: 3,173% year-over-year (YOY) sales growth Keeping in mind that it's starting from a small full-year... | Aurora Cannabis: 171% YOY sales growth No surprise here, either: The largest cannabis producer in the world, Aurora Cannabis (NYSE: ACB), should be one of the 10 fastest-growing pot stocks next year. Auxly Cannabis Group: 3,173% year-over-year (YOY) sales growth Keeping in mind that it's starting from a small full-year... |
38320.0 | 2019-06-29 00:00:00 UTC | Canadian Marijuana Sales Hit an All-Time High in April (but Still Disappoint) | ACB | https://www.nasdaq.com/articles/canadian-marijuana-sales-hit-an-all-time-high-in-april-but-still-disappoint-2019-06-29 | nan | nan | A decade or two from now, we may look back upon legal cannabis as the greatest growth story of our generation. Having recorded $10.9 billion in worldwide revenue last year, the legal weed industry is on track for a compound annual growth rate of more than 24% through 2024, according to Arcview Market Research and BDS A... | For example, profit projections for the three most popular cannabis stocks in the world -- Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), and Cronos Group (NASDAQ: CRON) -- have been falling precipitously for months. Having recorded $10.9 billion in worldwide revenue last year, the legal weed industry is on tr... | For example, profit projections for the three most popular cannabis stocks in the world -- Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), and Cronos Group (NASDAQ: CRON) -- have been falling precipitously for months. Since cannabis is a highly regulated market, the revenue data reported to Statistics Canada is... | For example, profit projections for the three most popular cannabis stocks in the world -- Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), and Cronos Group (NASDAQ: CRON) -- have been falling precipitously for months. Canada's legal weed revenue soared in April, but that's not saying much Unfortunately, the lau... | For example, profit projections for the three most popular cannabis stocks in the world -- Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), and Cronos Group (NASDAQ: CRON) -- have been falling precipitously for months. Canada's legal weed revenue soared in April, but that's not saying much Unfortunately, the lau... |
38321.0 | 2019-06-28 00:00:00 UTC | Aurora Cannabis Stock: Strong Potential, But This Isn’t the Time to Buy | ACB | https://www.nasdaq.com/articles/aurora-cannabis-stock%3A-strong-potential-but-this-isnt-the-time-to-buy-2019-06-28 | nan | nan | Aurora Cannabis (NYSE:) shares continue to tread water, with ACB stock trading around between $8-$9/share for the past few months. But is ACB stock a buy today?
Source: Shutterstock
Compared to its largest peer Canopy Growth (NYSE:), ACB stock offers investors a better value proposition. This is not to say Aurora is “c... | Source: Shutterstock Compared to its largest peer Canopy Growth (NYSE:), ACB stock offers investors a better value proposition. Aurora Cannabis (NYSE:) shares continue to tread water, with ACB stock trading around between $8-$9/share for the past few months. But is ACB stock a buy today? | Source: Shutterstock Compared to its largest peer Canopy Growth (NYSE:), ACB stock offers investors a better value proposition. ACB Stock Sells At a Rich Valuation, Despite Many Risks Trading at 61 times sales, Aurora Cannabis stock is no value play. Aurora Cannabis (NYSE:) shares continue to tread water, with ACB stoc... | ACB Stock Sells At a Rich Valuation, Despite Many Risks Trading at 61 times sales, Aurora Cannabis stock is no value play. Aurora Cannabis (NYSE:) shares continue to tread water, with ACB stock trading around between $8-$9/share for the past few months. But is ACB stock a buy today? | ACB Stock Sells At a Rich Valuation, Despite Many Risks Trading at 61 times sales, Aurora Cannabis stock is no value play. Aurora Cannabis (NYSE:) shares continue to tread water, with ACB stock trading around between $8-$9/share for the past few months. But is ACB stock a buy today? |
38322.0 | 2019-06-28 00:00:00 UTC | Why Aurora Cannabis Stock Might Fall to $6 Per Share Soon | ACB | https://www.nasdaq.com/articles/why-aurora-cannabis-stock-might-fall-to-%246-per-share-soon-2019-06-28 | nan | nan | Aurora Cannabis Inc. (NYSE: ) has largely continued its downward trend that started after ACB stock spiked above $10 in mid-March. Aurora stock is now in danger of falling below the $7.00 level. Although the weak quarterly earnings report from Canopy Growth Corporation (NYSE: ) may explain part of the drop, there are o... | Although the weak quarterly earnings report from Canopy Growth Corporation (NYSE: ) may explain part of the drop, there are other reasons for the selling pressure on ACB stock. Other Risks Facing ACB Stock The sequential declines in the revenue of Canopy Growth’s recreational, medical, and international businesses sugg... | Offering more products could spur increased sales for Aurora, benefiting Aurora’s results and ACB stock. If investors buy those names first instead of ACB stock, chances are good that Aurora Cannabis stock will drop. Aurora Cannabis Inc. (NYSE: ) has largely continued its downward trend that started after ACB stock spi... | Offering more products could spur increased sales for Aurora, benefiting Aurora’s results and ACB stock. If investors buy those names first instead of ACB stock, chances are good that Aurora Cannabis stock will drop. The Bottom Line on ACB Stock The recent downward pressure on Aurora stock is driven by negative emotion... | Offering more products could spur increased sales for Aurora, benefiting Aurora’s results and ACB stock. If investors buy those names first instead of ACB stock, chances are good that Aurora Cannabis stock will drop. Aurora Cannabis Inc. (NYSE: ) has largely continued its downward trend that started after ACB stock spi... |
38323.0 | 2019-06-27 00:00:00 UTC | Critical Levels to Watch in 7 Marijuana Stocks | ACB | https://www.nasdaq.com/articles/critical-levels-to-watch-in-7-marijuana-stocks-2019-06-27 | nan | nan | In financial markets, there are certain price levels that are more significant than others. Levels with important amounts of supply and demand. In addition, prices are always doing one of three things. They are either going up, going down or staying the same. When understood and applied correctly, technical analysis i... | ACB continues to trend lower after breaking support at the important $10.45 level (illustrated by the red line). Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) grows and sells medical cannabis. Then it was support throughout May before the ACB stock price finally broke it on the last day of the month. | Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) grows and sells medical cannabis. ACB continues to trend lower after breaking support at the important $10.45 level (illustrated by the red line). Then it was support throughout May before the ACB stock price finally broke it on the last day of the month. | Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) grows and sells medical cannabis. ACB continues to trend lower after breaking support at the important $10.45 level (illustrated by the red line). Then it was support throughout May before the ACB stock price finally broke it on the last day of the month. | Aurora Cannabis (ACB) Aurora Cannabis (NYSE:) grows and sells medical cannabis. ACB continues to trend lower after breaking support at the important $10.45 level (illustrated by the red line). Then it was support throughout May before the ACB stock price finally broke it on the last day of the month. |
38324.0 | 2019-06-27 00:00:00 UTC | August 9th Options Now Available For Aurora Cannabis (ACB) | ACB | https://www.nasdaq.com/articles/august-9th-options-now-available-for-aurora-cannabis-acb-2019-06-27 | nan | nan | Investors in Aurora Cannabis Inc (Symbol: ACB) saw new options become available today, for the August 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACB options chain for the new August 9th contracts and identified one put and one call contract of particular interest.
The pu... | Of course, a lot of upside could potentially be left on the table if ACB shares really soar, which is why looking at the trailing twelve month trading history for Aurora Cannabis Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACB's trailing twelve month trading history, w... | Below is a chart showing ACB's trailing twelve month trading history, with the $8.00 strike highlighted in red: Considering the fact that the $8.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibil... | Below is a chart showing ACB's trailing twelve month trading history, with the $8.00 strike highlighted in red: Considering the fact that the $8.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibil... | At Stock Options Channel, our YieldBoost formula has looked up and down the ACB options chain for the new August 9th contracts and identified one put and one call contract of particular interest. Below is a chart showing ACB's trailing twelve month trading history, with the $8.00 strike highlighted in red: Considering ... |
38325.0 | 2019-06-27 00:00:00 UTC | The First Canadian Pot Stock to Generate Recurring Profits Will Be... | ACB | https://www.nasdaq.com/articles/the-first-canadian-pot-stock-to-generate-recurring-profits-will-be...-2019-06-27 | nan | nan | The "canna-business" is booming, in case you haven't noticed. After generating a whopping $10.9 billion in legal sales last year in licensed stores, the newest "State of the Legal Cannabis Markets" report from the duo of Arcview Market Research and BDS Analytics projects that worldwide sales will top $40 billion by 202... | It won't be these four popular pot stocks Perhaps the easiest thing to do is remove the Canadian marijuana growers that we absolutely know won't be the answer, such as Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), and Tilray (NASDAQ: TLRY). Having been forced to purchase wholesale... | It won't be these four popular pot stocks Perhaps the easiest thing to do is remove the Canadian marijuana growers that we absolutely know won't be the answer, such as Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), and Tilray (NASDAQ: TLRY). After generating a whopping $10.9 billio... | It won't be these four popular pot stocks Perhaps the easiest thing to do is remove the Canadian marijuana growers that we absolutely know won't be the answer, such as Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), and Tilray (NASDAQ: TLRY). Although costs are likely to be high for... | It won't be these four popular pot stocks Perhaps the easiest thing to do is remove the Canadian marijuana growers that we absolutely know won't be the answer, such as Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), Cronos Group (NASDAQ: CRON), and Tilray (NASDAQ: TLRY). The Canadian cannabis stock with the bes... |
38326.0 | 2019-06-26 00:00:00 UTC | Health Canada Just Failed the Marijuana Industry... Again | ACB | https://www.nasdaq.com/articles/health-canada-just-failed-the-marijuana-industry...-again-2019-06-26 | nan | nan | In terms of growth prospects, no industry is blazing a trail quite like legal marijuana. The newly released "State of the Legal Cannabis Markets" report from Arcview Market Research and BDS Analytics calls for more than $40 billion in global licensed-store revenue by 2024, up from just under $11 billion in 2018 (a comp... | Aurora Cannabis (NYSE: ACB) is one such company that's not going to be pleased with this decision. Regulatory agency Health Canada laid out a series of guidelines that growers, processors, distributors, and retailers would need to follow if they wanted pot products to wind up on cannabis-store shelves. Roughly two week... | Aurora Cannabis (NYSE: ACB) is one such company that's not going to be pleased with this decision. In January and February, licensed cannabis store sales in Canada actually declined, with February sales coming in about 13% lower than where they were in December. As the agency tasked with reviewing and approving or deny... | Aurora Cannabis (NYSE: ACB) is one such company that's not going to be pleased with this decision. Canada's pot industry has faltered badly, thanks to Health Canada While this might seem like the perfect recipe for success, the launch of legal weed hasn't exactly been a budding success in Canada. Health Canada fails th... | Aurora Cannabis (NYSE: ACB) is one such company that's not going to be pleased with this decision. Health Canada fails the marijuana industry, once again But this isn't the only time that Health Canada has failed the marijuana industry. The impact on Canadian pot stocks could be mixed Even though all marijuana stocks a... |
38327.0 | 2019-06-26 00:00:00 UTC | No Real News Is Actually Good News for Aurora Cannabis Stock | ACB | https://www.nasdaq.com/articles/no-real-news-is-actually-good-news-for-aurora-cannabis-stock-2019-06-26 | nan | nan | Heading into another round of earnings reports, cannabis investors held their collective breath. After several rough sessions, sector leaders like Aurora Cannabis (NYSE:) needed a strong narrative. Having already issued its most-recent report in May, ACB stock depended on one of its competitors to provide that narrativ... | Having already issued its most-recent report in May, ACB stock depended on one of its competitors to provide that narrative. Does that mean investors should avoid ACB stock moving forward? ACB Stock Narrative Hasn’t Changed What’s perplexing to me is that the markets insist on punishing cannabis equities like ACB stock... | Having already issued its most-recent report in May, ACB stock depended on one of its competitors to provide that narrative. Does that mean investors should avoid ACB stock moving forward? ACB Stock Narrative Hasn’t Changed What’s perplexing to me is that the markets insist on punishing cannabis equities like ACB stock... | ACB Stock Narrative Hasn’t Changed What’s perplexing to me is that the markets insist on punishing cannabis equities like ACB stock on the same news. Aurora Stock Suffers from a Distorted View If that’s the case, the markets should stop judging ACB stock on common benchmarks like earnings per share. Having already issu... | ACB Stock Narrative Hasn’t Changed What’s perplexing to me is that the markets insist on punishing cannabis equities like ACB stock on the same news. Having already issued its most-recent report in May, ACB stock depended on one of its competitors to provide that narrative. Does that mean investors should avoid ACB sto... |
38328.0 | 2019-06-25 00:00:00 UTC | Bears May Have Gotten Too Pessimistic Too Fast on Hexo Stock | ACB | https://www.nasdaq.com/articles/bears-may-have-gotten-too-pessimistic-too-fast-on-hexo-stock | nan | nan | HEXO Corp. (NYSE:), the Canadian cannabis company, is in a tailspin. HEXO stock price is down about 20% this month, more than triple the June decline of the ETFMG Alternative Harvest ETF (NYSEARCA:MJ). The June swoon has HEXO stock price about 35% below its 52-week high, more than enough to officially put the marijuana... | HEXO stock price is down about 20% this month, more than triple the June decline of the ETFMG Alternative Harvest ETF (NYSEARCA:MJ). However, Hexo stock has arguably priced in plenty of bad news without accounting for its longer-term bullish catalysts, including geographic diversity. Additionally, HEXO is taking steps ... | HEXO Corp. (NYSE:), the Canadian cannabis company, is in a tailspin. HEXO’s Recent Woes HEXO does not garner the same level of attention as some of the larger marijuana stocks, such as Canopy Growth (NYSE:), Aurora Cannabis (NYSE:), Tilray (NASDAQ:), or Cronos Group (NASDAQ:). Those risks include Canadian authorities p... | HEXO’s Recent Woes HEXO does not garner the same level of attention as some of the larger marijuana stocks, such as Canopy Growth (NYSE:), Aurora Cannabis (NYSE:), Tilray (NASDAQ:), or Cronos Group (NASDAQ:). Recently, Jefferies analyst Owen Bennett, who has an “underperform” rating on Hexo stock, pared his price targe... | The company controls 30% of Quebec’s marijuana market. The company is expected to post revenue of C$62.62 million in 2019, a figure that could run to C$320 million in 2020. Investors who grab Hexo stock right now may not have the smoothest of rides, but if its revenue growth over the next 12 months meets or beats expec... |
38329.0 | 2019-06-25 00:00:00 UTC | Aurora Stock Is a Sleeping Giant in the Cannabis Sector | ACB | https://www.nasdaq.com/articles/aurora-stock-is-a-sleeping-giant-in-the-cannabis-sector-2019-06-25 | nan | nan | Like a deflating tire, the North American cannabis index has been slowly sinking since mid-March, testing investors’ patience and enthusiasm for the sector. And just as a rising tide lifts all boats, a sinking tide can pull all ships down with it. In this case, it’s Aurora Cannabis (NYSE:) stock that’s being pulled und... | ACB Stock Boasts Geographic Diversification Sure, Aurora is the second-largest Canadian cultivator by market cap ($10.1 billion, to be exact), but there’s more to Aurora than its considerable presence in the Great White North. Combined, these two companies have over 170 million square feet of hemp under contract — a pr... | ACB Stock Boasts Geographic Diversification Sure, Aurora is the second-largest Canadian cultivator by market cap ($10.1 billion, to be exact), but there’s more to Aurora than its considerable presence in the Great White North. Last year, Aurora acquired two sister companies: Agropro UAB, Europe’s largest producer, proc... | ACB Stock Boasts Geographic Diversification Sure, Aurora is the second-largest Canadian cultivator by market cap ($10.1 billion, to be exact), but there’s more to Aurora than its considerable presence in the Great White North. Big Money Is Flowing In If you consider large-scale institutional buying to be an indicator o... | ACB Stock Boasts Geographic Diversification Sure, Aurora is the second-largest Canadian cultivator by market cap ($10.1 billion, to be exact), but there’s more to Aurora than its considerable presence in the Great White North. In fact, the reveals 9.35% institutional ownership, impressive within the cannabis industry; ... |
38330.0 | 2019-06-25 00:00:00 UTC | The Surprising Pot Stock Forecast to Lead the Industry in 2020 Sales | ACB | https://www.nasdaq.com/articles/the-surprising-pot-stock-forecast-to-lead-the-industry-in-2020-sales-2019-06-25 | nan | nan | For years now, much of Wall Street has believed that legal marijuana is the greatest investment opportunity since sliced bread. Investors are fully aware of the massive black market and understand that ongoing legalizations around the world could move tens of billions of dollars into legal channels in the years to come... | For example, the three largest marijuana growers by peak annual output -- Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), and Aphria (NYSE: APHA) -- rank fourth, second, and third, respectively, in fiscal 2020 sales, based on Wall Street's consensus. Canopy Growth is expected to generate close to $580 million i... | For example, the three largest marijuana growers by peak annual output -- Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), and Aphria (NYSE: APHA) -- rank fourth, second, and third, respectively, in fiscal 2020 sales, based on Wall Street's consensus. Aurora Cannabis should be yielding 625,000 kilos on an annual... | For example, the three largest marijuana growers by peak annual output -- Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), and Aphria (NYSE: APHA) -- rank fourth, second, and third, respectively, in fiscal 2020 sales, based on Wall Street's consensus. These five well-known marijuana stocks should top $500 millio... | For example, the three largest marijuana growers by peak annual output -- Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), and Aphria (NYSE: APHA) -- rank fourth, second, and third, respectively, in fiscal 2020 sales, based on Wall Street's consensus. 6 pot stock, with expected sales of $511 million. This surpri... |
38331.0 | 2019-06-25 00:00:00 UTC | Over Half of Canopy Growth's Huge Q4 Operating Loss Resulted From This Surprising Reason | ACB | https://www.nasdaq.com/articles/over-half-of-canopy-growths-huge-q4-operating-loss-resulted-from-this-surprising-reason | nan | nan | Canopy Growth (NYSE: CGC) didn't exactly wow investors with its fiscal 2019 fourth-quarter results last week. The Canadian cannabis producer reported lower quarter-over-quarter cannabis sales on all fronts, although overall revenue increased thanks primarily to its acquisition of German vaporizer device maker Storz & B... | As you might expect, increased spending on sales and marketing as well as general and administrative functions played a big role in Canopy's wider operating loss. Bruce Linton, Canopy Growth founder and co-CEO, defended his company's huge employee stock expense in a phone interview with MarketWatch last Friday. Over th... | The Canadian cannabis producer reported lower quarter-over-quarter cannabis sales on all fronts, although overall revenue increased thanks primarily to its acquisition of German vaporizer device maker Storz & Bickel. Over the long run, the issue about Canopy's employee stock options could be made irrelevant by the comp... | Because Canopy Growth stock rose, the company had to increase its expense associated with those notes, which will be able to be converted into stock in the future. Linton's idea is that every employee at Canopy Growth and other cannabis companies with a salary of less than CA$200,000 should receive 1.5 times their sala... | Because Canopy Growth stock rose, the company had to increase its expense associated with those notes, which will be able to be converted into stock in the future. His view is that granting options to employees makes the overall business stronger. Most probably aren't bothered too much by the company's employee stock o... |
38332.0 | 2019-06-24 00:00:00 UTC | Monday’s Vital Data: Canopy Growth Corp, Microsoft and Netflix | ACB | https://www.nasdaq.com/articles/mondays-vital-data%3A-canopy-growth-corp-microsoft-and-netflix-2019-06-24 | nan | nan | U.S. stock futures are trading higher this morning.
Heading into the open, futures on the Dow Jones Industrial Average are up 0.24%, and S&P 500 futures are higher by 0.21%. Nasdaq-100 futures have added 0.30%.
In the options pits, call trading carried equities into the weekend, even as overall volume settled at above-... | Fellow pot stocks Cronos Group (NASDAQ:) and Aurora Cannabis (NYSE:) both fell in sympathy, though their losses were pared before the closing bell. Friday’s plunge landed CGC at the lower end of its multi-month trading range and places it on precarious footing heading into the new week. Given the utter lack of directio... | Let’s take a closer look: Canopy Growth Corp (CGC) Last week’s earnings report provided little help to Canopy Growth Corp’s struggling stock price. On the options trading front, traders favored calls over puts on the session despite the thrashing. Activity popped to 131% of the average daily volume, with 206,455 total ... | In the options pits, call trading carried equities into the weekend, even as overall volume settled at above-average levels. Activity popped to 131% of the average daily volume, with 206,455 total contracts traded; 62% of the trading came from call options alone. Total activity ramped to 156% of the average daily volum... | U.S. stock futures are trading higher this morning. In the options pits, call trading carried equities into the weekend, even as overall volume settled at above-average levels. On the options trading front, traders favored calls over puts on the session despite the thrashing. |
38333.0 | 2019-06-24 00:00:00 UTC | The 10 Most Important Numbers in Canopy Growth's Fourth-Quarter Report | ACB | https://www.nasdaq.com/articles/the-10-most-important-numbers-in-canopy-growths-fourth-quarter-report-2019-06-24 | nan | nan | The most prized earnings report throughout the marijuana industry is now in the books. Following the closing bell on Thursday, June 20, Canopy Growth (NYSE: CGC), the largest marijuana stock in the world by market cap, lifted the hood on its fourth-quarter and full-year operating results.
While the headline figures hon... | More than 4.7 million square feet of production space Both Aurora Cannabis (NYSE: ACB) and Canopy Growth are in a league of their own when it comes to peak annual output. Following the closing bell on Thursday, June 20, Canopy Growth (NYSE: CGC), the largest marijuana stock in the world by market cap, lifted the hood o... | More than 4.7 million square feet of production space Both Aurora Cannabis (NYSE: ACB) and Canopy Growth are in a league of their own when it comes to peak annual output. Gross recreational revenue actually declined from the sequential quarter (all figures in Canadian dollars) from CA$71.6 million to CA$68.9 million, w... | More than 4.7 million square feet of production space Both Aurora Cannabis (NYSE: ACB) and Canopy Growth are in a league of their own when it comes to peak annual output. Gross recreational revenue actually declined from the sequential quarter (all figures in Canadian dollars) from CA$71.6 million to CA$68.9 million, w... | More than 4.7 million square feet of production space Both Aurora Cannabis (NYSE: ACB) and Canopy Growth are in a league of their own when it comes to peak annual output. Ancillary revenue soared to CA$24.2 million As promised earlier, the star of Canopy Growth's report wasn't marijuana growth, because organic sales ac... |
38334.0 | 2019-06-23 00:00:00 UTC | 3 Potential Catalysts That Could Cause Aurora Cannabis Stock to Skyrocket | ACB | https://www.nasdaq.com/articles/3-potential-catalysts-that-could-cause-aurora-cannabis-stock-to-skyrocket-2019-06-23 | nan | nan | Aurora Cannabis' (NYSE: ACB) sizzle seems to have fizzled. The Canadian marijuana stock more than doubled by the middle of March. Since then, though, Aurora has given up roughly half of its big gain.
But don't think for a second that Aurora can't turn up the heat yet again. The company continues to pick up momentum in ... | Aurora Cannabis' (NYSE: ACB) sizzle seems to have fizzled. Even if Aurora doesn't get a lot of cash with a partnership, though, teaming up with one or more high-profile companies from outside the cannabis industry should light a fire beneath the stock. In January, Aurora Chief Corporate Officer Cam Battley told Busines... | Aurora Cannabis' (NYSE: ACB) sizzle seems to have fizzled. Landing a big partner Several of the top Canadian marijuana producers have landed big partners from outside the cannabis industry. Canopy Growth (NYSE: CGC) teamed up with large alcoholic-beverage maker Constellation Brands (NYSE: STZ). | Aurora Cannabis' (NYSE: ACB) sizzle seems to have fizzled. A major move into the U.S. hemp CBD market Aurora also lags behind some of its peers in making a major move into the U.S. hemp cannabidiol (CBD) market. And as long as that remains the case, Aurora won't be able to jump into the U.S. marijuana market and keep i... | Aurora Cannabis' (NYSE: ACB) sizzle seems to have fizzled. Landing a big partner Several of the top Canadian marijuana producers have landed big partners from outside the cannabis industry. I think the probability of Aurora landing at least one major partner from outside the cannabis industry is very high -- at least 8... |
38335.0 | 2019-06-23 00:00:00 UTC | 5 Most Popular Marijuana Stocks on the Market Right Now | ACB | https://www.nasdaq.com/articles/5-most-popular-marijuana-stocks-on-the-market-right-now-2019-06-23 | nan | nan | What are the most popular marijuana stocks on the market right now? It depends on how you measure popularity.
Probably the best way to evaluate the popularity of a stock is to look at its average daily trading volume. This number provides a great barometer of investor interest in a given stock. You might argue that som... | Based on average trading volume, the most popular marijuana stocks on the market right now are Aphria (NYSE: APHA), Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), Cronos Group (NASDAQ: CRON), and HEXO (NYSEMKT: HEXO) (TSX: HEXO). In addition, Aurora's efforts to find a big partner from outside the cannabis ind... | Based on average trading volume, the most popular marijuana stocks on the market right now are Aphria (NYSE: APHA), Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), Cronos Group (NASDAQ: CRON), and HEXO (NYSEMKT: HEXO) (TSX: HEXO). Another is that Aurora claims the second-highest market share in Canada's adult-u... | Based on average trading volume, the most popular marijuana stocks on the market right now are Aphria (NYSE: APHA), Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), Cronos Group (NASDAQ: CRON), and HEXO (NYSEMKT: HEXO) (TSX: HEXO). Aurora's average daily trading volume over the last three months is over 17.9 mil... | Based on average trading volume, the most popular marijuana stocks on the market right now are Aphria (NYSE: APHA), Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), Cronos Group (NASDAQ: CRON), and HEXO (NYSEMKT: HEXO) (TSX: HEXO). What are the most popular marijuana stocks on the market right now? Which of thes... |
38336.0 | 2019-06-22 00:00:00 UTC | Here's Why This REIT Could Be the Best Cannabis Stock You've Never Heard Of | ACB | https://www.nasdaq.com/articles/heres-why-this-reit-could-be-the-best-cannabis-stock-youve-never-heard-of-2019-06-22 | nan | nan | Over the past 12 months, the amount of search traffic driven by Innovative Industrial Properties (NYSE: IIPR) barely registered when compared to large cannabis producers like Aurora Cannabis (NYSE: ACB). You might be surprised to learn that over the same period, IIP's stock price has soared 252% because it has somethin... | Over the past 12 months, the amount of search traffic driven by Innovative Industrial Properties (NYSE: IIPR) barely registered when compared to large cannabis producers like Aurora Cannabis (NYSE: ACB). If you're surprised to see shares of a dull landlord business outperforming marijuana stocks that receive heaps more... | Over the past 12 months, the amount of search traffic driven by Innovative Industrial Properties (NYSE: IIPR) barely registered when compared to large cannabis producers like Aurora Cannabis (NYSE: ACB). IIP's making money now Nearly all the cannabis industry giants, Aurora Cannabis included, have been issuing new shar... | Over the past 12 months, the amount of search traffic driven by Innovative Industrial Properties (NYSE: IIPR) barely registered when compared to large cannabis producers like Aurora Cannabis (NYSE: ACB). You might be surprised to learn that over the same period, IIP's stock price has soared 252% because it has somethin... | Over the past 12 months, the amount of search traffic driven by Innovative Industrial Properties (NYSE: IIPR) barely registered when compared to large cannabis producers like Aurora Cannabis (NYSE: ACB). You might be surprised to learn that over the same period, IIP's stock price has soared 252% because it has somethin... |
38337.0 | 2019-06-21 00:00:00 UTC | Akerna Stock Offers Investors a New Way to Play the Cannabis Craze | ACB | https://www.nasdaq.com/articles/akerna-stock-offers-investors-a-new-way-to-play-the-cannabis-craze-2019-06-21 | nan | nan | Investors, meet Akerna (NASDAQ:), the newest marijuana stock to hit the market. Akerna is fundamentally different from many other marijuana stocks in two important ways. One, it’s a U.S. company, whereas most pot stocks are Canadian ventures. Secondly, Akerna isn’t a cannabis producer; it’s a cannabis-technology compan... | As of this writing, Luke Lango was long CGC and ACB. Simply put, the biggest players in the cannabis space are producers, and pot still isn’t legal in all of the U.S. Against that backdrop, Akerna’s plunge into the public market is very interesting. KERN’s other meaningful business is broadly dubbed enterprise resource... | As of this writing, Luke Lango was long CGC and ACB. Right now, because we are in the top of the first inning of the cannabis sector’s growth, investors’ potential exposure to the legal cannabis industry is largely limited to Canadian cannabis producers like Canopy Growth (NYSE:), Cronos (NASDAQ:), Aurora (NYSE:), and ... | As of this writing, Luke Lango was long CGC and ACB. Right now, because we are in the top of the first inning of the cannabis sector’s growth, investors’ potential exposure to the legal cannabis industry is largely limited to Canadian cannabis producers like Canopy Growth (NYSE:), Cronos (NASDAQ:), Aurora (NYSE:), and ... | As of this writing, Luke Lango was long CGC and ACB. What Does Akerna Do? Overall, then, Akerna is a cannabis-tech company which sells important technology solutions to cannabis industry regulators, cannabis producers, and retail cannabis companies. |
38338.0 | 2019-06-21 00:00:00 UTC | ACB Stock Is a Buy Because Aurora Cannabis Won’t Get Left in the Dust | ACB | https://www.nasdaq.com/articles/acb-stock-is-a-buy-because-aurora-cannabis-wont-get-left-in-the-dust-2019-06-21 | nan | nan | With the markets near all-time highs, there has been a nice rally in cannabis stocks, but Aurora Cannabis (NYSE:) seems to have missed the memo. ACB stock has been languishing.
Source: Shutterstock
During the past couple weeks, Tilray (NASDAQ:) has logged a return of 32% while Cronos Group (NASDAQ:) is up about 17% and... | Other Opportunities for ACB Stock Another important development is a recent partnership with the Ultimate Fighting Championship (UFC), which is the world’s largest martial arts organization. ACB stock has been languishing. Unfortunately, ACB stock has been in an extended downtrend, going from $10 in March to $7.48. | Other Opportunities for ACB Stock Another important development is a recent partnership with the Ultimate Fighting Championship (UFC), which is the world’s largest martial arts organization. ACB stock has been languishing. Unfortunately, ACB stock has been in an extended downtrend, going from $10 in March to $7.48. | CBD for both medical and wellness applications has incredible potential and we intend to fully leverage our capabilities, our infrastructure and our partnership potential to maximize shareholder value creation.” Bottom Line on ACB Stock In mid-May, Aurora brought on board as a strategic advisor Nelson Peltz, who is the... | If anything, the recent weakness does make ACB stock look relatively attractive. ACB stock has been languishing. Unfortunately, ACB stock has been in an extended downtrend, going from $10 in March to $7.48. |
38339.0 | 2019-06-21 00:00:00 UTC | When The Global Cannabis Shake-out Comes, Will Tilray Still Be A Leader? | ACB | https://www.nasdaq.com/articles/when-the-global-cannabis-shake-out-comes-will-tilray-still-be-a-leader-2019-06-21 | nan | nan | Tilray (NASDAQ:) CFO Mark Castaneda believes “only three or four large players” will control 80% of the global cannabis market with thousands of companies fighting for the remaining 20% market share. So, you can forget about the global cannabis market benefiting lots of different companies.
Source: Shutterstock
The... | With its to buy Acreage Holdings (OTCMKTS:ACRGF) approved by both companies’ shareholders, the fact that Tilray CEO Brendan Kennedy the U.S. federal government will legalize cannabis within three years suggests Canopy is getting one of the biggest U.S. producers at a very reasonable price. While it’s still early in the... | Currently, TLRY is the Canadian cannabis stock with a market cap of $4.4 billion, $900 million behind Cronos Group (NASDAQ:CRON) in the third position and $3.3 billion behind Aurora Cannabis (NYSE:) in the second spot. Therefore, let’s say Canopy, Curaleaf, a cannabis company outside North America, and one more North A... | Tilray (NASDAQ:) CFO Mark Castaneda believes “only three or four large players” will control 80% of the global cannabis market with thousands of companies fighting for the remaining 20% market share. Therefore, let’s say Canopy, Curaleaf, a cannabis company outside North America, and one more North American company mak... | With its to buy Acreage Holdings (OTCMKTS:ACRGF) approved by both companies’ shareholders, the fact that Tilray CEO Brendan Kennedy the U.S. federal government will legalize cannabis within three years suggests Canopy is getting one of the biggest U.S. producers at a very reasonable price. Therefore, let’s say Canopy, ... |
38340.0 | 2019-06-20 00:00:00 UTC | The 4 Biggest Cannabis Question Marks for the Second Half of 2019 | ACB | https://www.nasdaq.com/articles/the-4-biggest-cannabis-question-marks-for-the-second-half-of-2019-2019-06-20 | nan | nan | Over the past couple of years, marijuana has been a significant moneymaker for investors. Although not every pot stock has moved higher, buying a handful of the most popular growers and ancillary players would likely have yielded a return that ran circles around the broader market.
There are, however, pretty big questi... | Sure, Aurora Cannabis (NYSE: ACB) may just be one pot stock among dozens of possible investment choices, but it also happens to be the projected leading producer of cannabis in the world. Although not every pot stock has moved higher, buying a handful of the most popular growers and ancillary players would likely have ... | Sure, Aurora Cannabis (NYSE: ACB) may just be one pot stock among dozens of possible investment choices, but it also happens to be the projected leading producer of cannabis in the world. 3 grower in Canada at 255,000 kilos a year, when fully operational, has been waiting more than a year for Health Canada to OK its Ap... | Sure, Aurora Cannabis (NYSE: ACB) may just be one pot stock among dozens of possible investment choices, but it also happens to be the projected leading producer of cannabis in the world. Earlier this year, Health Canada signaled its intentions to legalize these alternative consumption options by no later than the one-... | Sure, Aurora Cannabis (NYSE: ACB) may just be one pot stock among dozens of possible investment choices, but it also happens to be the projected leading producer of cannabis in the world. Can Health Canada make a dent in its application backlog? 3 grower in Canada at 255,000 kilos a year, when fully operational, has be... |
38341.0 | 2019-06-20 00:00:00 UTC | Robinhood’s Users Love Aurora Stock: Should You? | ACB | https://www.nasdaq.com/articles/robinhoods-users-love-aurora-stock%3A-should-you-2019-06-20 | nan | nan | According to Investor’s Business Daily, Aurora Cannabis (NYSE:) is the most widely held equity on Robinhood. That’s the commission-free trading platform popular with millennials and Gen Z-ers.
Source: Shutterstock
So, does the fact that millennials and Gen Z-ers are bullish on ACB stock make it a buy?
Here are argument... | InvestorPlace feature writer James Brumley recently wrote a piece about ACB stock that the moves the company’s making to diversify its holdings beyond Canada. And despite the negatives, at the end of the day, the fact that Robinhood users love ACB stock is further confirmation Aurora’s making all the right moves. Sourc... | Youthful Exuberance for Aurora Stock Is Also a Risk Here’s the big problem with Aurora sitting on pole position for Robinhood’s list: millennials may view the volatility of ACB stock and cannabis investments in general as a pathway to quick riches. Source: Shutterstock So, does the fact that millennials and Gen Z-ers a... | Youthful Exuberance for Aurora Stock Is Also a Risk Here’s the big problem with Aurora sitting on pole position for Robinhood’s list: millennials may view the volatility of ACB stock and cannabis investments in general as a pathway to quick riches. Source: Shutterstock So, does the fact that millennials and Gen Z-ers a... | Source: Shutterstock So, does the fact that millennials and Gen Z-ers are bullish on ACB stock make it a buy? InvestorPlace feature writer James Brumley recently wrote a piece about ACB stock that the moves the company’s making to diversify its holdings beyond Canada. Millennial Ownership of ACB Stock Is a Big Deal No ... |
38342.0 | 2019-06-19 00:00:00 UTC | Profit Projections Are Still Plunging for the 3 Most Popular Pot Stocks | ACB | https://www.nasdaq.com/articles/profit-projections-are-still-plunging-for-the-3-most-popular-pot-stocks-2019-06-19 | nan | nan | Legal marijuana projects as one of the fastest-growing industries for the next couple of years. It generated $12.2 billion in global sales in 2018, and the team of Arcview Market Research and BDS Analytics have forecast worldwide revenue of $31.3 billion by 2022. This works out to a compound annual growth rate of 26.6%... | Marijuana's most popular stocks are turning into fundamental nightmares A quick examination of the three most popular pot stocks -- Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), and Cronos Group (NASDAQ: CRON) -- reveals that Wall Street's fiscal 2020 consensus estimate for these companies continues to plunge... | Marijuana's most popular stocks are turning into fundamental nightmares A quick examination of the three most popular pot stocks -- Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), and Cronos Group (NASDAQ: CRON) -- reveals that Wall Street's fiscal 2020 consensus estimate for these companies continues to plunge... | Marijuana's most popular stocks are turning into fundamental nightmares A quick examination of the three most popular pot stocks -- Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), and Cronos Group (NASDAQ: CRON) -- reveals that Wall Street's fiscal 2020 consensus estimate for these companies continues to plunge... | Marijuana's most popular stocks are turning into fundamental nightmares A quick examination of the three most popular pot stocks -- Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), and Cronos Group (NASDAQ: CRON) -- reveals that Wall Street's fiscal 2020 consensus estimate for these companies continues to plunge... |
38343.0 | 2019-06-18 00:00:00 UTC | Canopy Growth Stock Has One Massive Lever: Job Growth | ACB | https://www.nasdaq.com/articles/canopy-growth-stock-has-one-massive-lever%3A-job-growth-2019-06-18 | nan | nan | There are many ways of looking at the exciting but volatile marijuana industry. Based on my own admittedly anecdotal perspective, I’d guess that most people take the fundamental approach. For instance, they view companies like Canopy Growth (NYSE:) using traditional metrics like revenue and earnings growth. I think tha... | Let’s be real: The reason why marijuana investments like Aurora Cannabis (NYSE:) and Hexo (AMEX:) have disappointed recently is Canada. Canopy Growth Stock Sitting on a Goldmine Piper Jaffray analyst Michael Lavery recently wrote to clients that he expects U.S. legalization “in the next 1.5-4.5 years.” I’m with him. If... | For instance, they view companies like Canopy Growth (NYSE:) using traditional metrics like revenue and earnings growth. Let’s be real: The reason why marijuana investments like Aurora Cannabis (NYSE:) and Hexo (AMEX:) have disappointed recently is Canada. But right now, the feds are playing Hanoi Jane with the America... | After all, if Canopy stock wasn’t a marijuana play, who would invest in a company that went from a loss of less than $6 million in 2017 to over $300 million in the trailing 12-month period? But even if those issues are resolved soon, the real focus for CGC stock has always been the U.S. It’s All About Jobs for CGC Stoc... | For instance, they view companies like Canopy Growth (NYSE:) using traditional metrics like revenue and earnings growth. But even if those issues are resolved soon, the real focus for CGC stock has always been the U.S. It’s All About Jobs for CGC Stock On the surface, this is a bold statement for Canopy Growth stock. A... |
38344.0 | 2019-06-18 00:00:00 UTC | Hexo Stock Remains Attractive Despite Revenue Miss | ACB | https://www.nasdaq.com/articles/hexo-stock-remains-attractive-despite-revenue-miss-2019-06-18 | nan | nan | Hexo (NYSE:) reported third-quarter earnings Thursday before the bell. The Quebec-based cannabis company’s revenues missed analysts’ estimate by a wide margin and even declined versus Q2, causing HEXO stock to plunge on both Thursday and Friday.
Still, while this report might have scared investors, it does not appea... | The Quebec-based cannabis company’s revenues missed analysts’ estimate by a wide margin and even declined versus Q2, causing HEXO stock to plunge on both Thursday and Friday. However, by focusing on that revenue number, investors apparently ignored an acquisition that will dramatically increase both the company’s pr... | Still, while this report might have scared investors, it does not appear to have affected the overall trajectory of Hexo Corp. HEXO Fell on a Massive Revenue Miss The HEXO stock price fell by another 5% on Friday. That came on top of an 8.5% decline on Thursday, as the fallout from the sequential revenue decline sent H... | The Quebec-based cannabis company’s revenues missed analysts’ estimate by a wide margin and even declined versus Q2, causing HEXO stock to plunge on both Thursday and Friday. Still, while this report might have scared investors, it does not appear to have affected the overall trajectory of Hexo Corp. HEXO Fell on a ... | In this province of about 8.4 million people, HEXO controls more than 30% of the cannabis market. Should Investors Buy HEXO Stock? Given its growth potential, investors should add to their positions in HEXO, instead of selling HEXO stock. |
38345.0 | 2019-06-18 00:00:00 UTC | Diversification Is What Makes Aurora Stock a Solid Marijuana Play | ACB | https://www.nasdaq.com/articles/diversification-is-what-makes-aurora-stock-a-solid-marijuana-play-2019-06-18 | nan | nan | Late last month I fleshed out some thoughts on Aurora Cannabis (NYSE:), ultimately deciding that an investment in Aurora stock was mostly an investment in medical marijuana with an emphasis on Europe.
Source: Aurora Cannabis
It’s a difference that still doesn’t entirely matter. While Canopy Growth (NYSE:) appears to be... | But, as laws progress and minds are changed, it’s likely that restrictions currently making importing and exporting cannabis incredibly difficult will be eased. The deal not only gave Aurora 70% of the Uruguayan recreational market, but it also grants the new owners licenses to grow medical marijuana in Colombia and pl... | The moves, and others like them, put North American companies into a Latin American cannabis market expected to be ; most of that would be sales of medicinal cannabis. That makes Latin America a marijuana hub that Aurora isn’t a part of. The deal not only gave Aurora 70% of the Uruguayan recreational market, but it als... | Late last month I fleshed out some thoughts on Aurora Cannabis (NYSE:), ultimately deciding that an investment in Aurora stock was mostly an investment in medical marijuana with an emphasis on Europe. There’s yet-another nuance to Aurora Cannabis that keeps Aurora stock at the upper portion of a list of marijuana stock... | That makes Latin America a marijuana hub that Aurora isn’t a part of. Aurora Stock and Latin America The company seems vulnerable on the surface. Aurora Cannabis . |
38346.0 | 2019-06-17 00:00:00 UTC | 5 Stocks to Buy for $20 or Less | ACB | https://www.nasdaq.com/articles/5-stocks-to-buy-for-%2420-or-less-2019-06-17 | nan | nan | A good rule of thumb in the stock market is to not buy stocks just because they are cheap or low. Cheap stocks, or stocks that trade at discounted valuation multiples, are often cheap for a reason. The same is true for low-price stocks, or stocks that trade in the under-$10 and under-$20 ranges.
As such, when dealing w... | Aurora Cannabis (ACB) Source: Aurora Cannabis Stock Price: $7.50 In the under $10 category, one of the more attractive stocks to buy is undervalued Canadian cannabis producer Aurora (NYSE:). That relative cheapness in ACB stock comes despite Aurora having many strengths. Why, then, is ACB stock cheap relative to peers? | Aurora Cannabis (ACB) Source: Aurora Cannabis Stock Price: $7.50 In the under $10 category, one of the more attractive stocks to buy is undervalued Canadian cannabis producer Aurora (NYSE:). That relative cheapness in ACB stock comes despite Aurora having many strengths. Why, then, is ACB stock cheap relative to peers? | Aurora Cannabis (ACB) Source: Aurora Cannabis Stock Price: $7.50 In the under $10 category, one of the more attractive stocks to buy is undervalued Canadian cannabis producer Aurora (NYSE:). That relative cheapness in ACB stock comes despite Aurora having many strengths. Why, then, is ACB stock cheap relative to peers? | Aurora Cannabis (ACB) Source: Aurora Cannabis Stock Price: $7.50 In the under $10 category, one of the more attractive stocks to buy is undervalued Canadian cannabis producer Aurora (NYSE:). That relative cheapness in ACB stock comes despite Aurora having many strengths. Why, then, is ACB stock cheap relative to peers? |
38347.0 | 2019-06-17 00:00:00 UTC | Avoid Getting Burned by Aurora Cannabis (ACB) Stock | ACB | https://www.nasdaq.com/articles/avoid-getting-burned-by-aurora-cannabis-acb-stock-2019-06-17 | nan | nan | The high times for Aurora Cannabis (NYSE:) have certainly come down over the past couple months. But before you think a cheaper-priced ACB stock means better value, risks off and on the price chart remain. Let me explain.
Source: Aurora Cannabis
There’s still a lot of buzz surrounding the cannabis industry and plenty o... | But massive goodwill tied to ACB stock’s aggressive acquisition strategy over the past couple years is approaching 60% of the company’s valuation and a definite yellow flag for investors. But before you think a cheaper-priced ACB stock means better value, risks off and on the price chart remain. It would also be neglec... | But massive goodwill tied to ACB stock’s aggressive acquisition strategy over the past couple years is approaching 60% of the company’s valuation and a definite yellow flag for investors. ACB Stock Weekly Chart The risks on ACB stock’s price chart also shouldn’t be overlooked. But before you think a cheaper-priced ACB ... | But massive goodwill tied to ACB stock’s aggressive acquisition strategy over the past couple years is approaching 60% of the company’s valuation and a definite yellow flag for investors. ACB Stock Weekly Chart The risks on ACB stock’s price chart also shouldn’t be overlooked. But before you think a cheaper-priced ACB ... | ACB Stock Weekly Chart The risks on ACB stock’s price chart also shouldn’t be overlooked. But before you think a cheaper-priced ACB stock means better value, risks off and on the price chart remain. It would also be neglectful to not respect some of ACB stock’s company-specific risks. |
38348.0 | 2019-06-17 00:00:00 UTC | The Top 5 Marijuana Investing Mistakes to Avoid | ACB | https://www.nasdaq.com/articles/the-top-5-marijuana-investing-mistakes-to-avoid-2019-06-17 | nan | nan | Over the past couple of years, few, if any, industries have beaten the returns offered by marijuana stocks. Some of the most popular pot stocks in the industry have delivered returns that, in some instances, have topped 2,000% since the beginning of 2016.
It's not hard to understand why investors are so bullish on the ... | Easily the worst offender of the bunch is popular pot stock Aurora Cannabis (NYSE: ACB). But despite the relative ease of making money in pot stocks over the past few years, it's just as easy to fall victim to one of the top five marijuana investing mistakes, which are listed below in no particular order. For instance,... | Easily the worst offender of the bunch is popular pot stock Aurora Cannabis (NYSE: ACB). Following 15 acquisitions in less than three years, nearly all of which were financed entirely by the company's common stock, Aurora's share count has ballooned from 16 million shares to just north of 1.01 billion. All told, Aurora... | Easily the worst offender of the bunch is popular pot stock Aurora Cannabis (NYSE: ACB). Focusing on price, not market cap Another easy mistake to make is focusing too much on a marijuana stock's share price, rather than its market cap. Share-price bias is the idea that a stock with a low share price, say $0.75 or perh... | Easily the worst offender of the bunch is popular pot stock Aurora Cannabis (NYSE: ACB). Buying what's popular Maybe the easiest way to lose money with cannabis stocks is by chasing the next-hottest intra-industry trend or purchasing a pot stock that everyone else considers to be "popular." Following 15 acquisitions in... |
38349.0 | 2019-06-17 00:00:00 UTC | Hexo Stock Has An Earnings Buzz Kill That Simply Isn’t Deserved | ACB | https://www.nasdaq.com/articles/hexo-stock-has-an-earnings-buzz-kill-that-simply-isnt-deserved-2019-06-17 | nan | nan | With many cannabis stocks at sky-high valuations, there’s little room for making mistakes. Just look at Hexo (NYSEAmerican:). On news of its latest earnings report, the stock price dropped 8.53%. Note that the HEXO stock price is about 50% off its 52-week high.
Source: Shutterstock
So let’s drill-down on the quarter. F... | The company announced it received a medical cannabis from the Greek government for “cultivation, processing and manufacturing facilities.” To this end, Hexo plans to begin construction of a 323,000 square-foot facility in the country by the fourth quarter of this year. There are also aggressive plans to benefit from th... | On news of its latest earnings report, the stock price dropped 8.53%. HEXO reported a loss of 7.75 million CAD ($5.77 million) , or 4 cents a share, while the was for a loss of 5 cents a share. Bottom Line on Hexo Stock According to InvestorPlace’s James Brumley, Hexo stock has been mostly overlooked — say compared to ... | HEXO reported a loss of 7.75 million CAD ($5.77 million) , or 4 cents a share, while the was for a loss of 5 cents a share. The company announced it received a medical cannabis from the Greek government for “cultivation, processing and manufacturing facilities.” To this end, Hexo plans to begin construction of a 323,00... | Note that the HEXO stock price is about 50% off its 52-week high. Bottom Line on Hexo Stock According to InvestorPlace’s James Brumley, Hexo stock has been mostly overlooked — say compared to names like Canopy Growth (NYSE:), Tilray (NASDAQ:), Aurora Cannabis (NYSE:) and Cronos Group (NASDAQ:). They not only call for a... |
38350.0 | 2019-06-16 00:00:00 UTC | Better Buy: Aurora Cannabis vs. Gilead Sciences | ACB | https://www.nasdaq.com/articles/better-buy%3A-aurora-cannabis-vs.-gilead-sciences-2019-06-16 | nan | nan | If you've never heard Canadian cannabis producer Aurora Cannabis (NYSE: ACB) and big biotech Gilead Sciences (NASDAQ: GILD) mentioned in the same sentence, this will be a first for you. You might not think that Aurora and Gilead have anything in common, but they do. Both companies are currently conducting clinical tria... | If you've never heard Canadian cannabis producer Aurora Cannabis (NYSE: ACB) and big biotech Gilead Sciences (NASDAQ: GILD) mentioned in the same sentence, this will be a first for you. Gilead is also actively developing drugs to treat nonalcoholic steatohepatitis (NASH), a market that some observers think could eventu... | If you've never heard Canadian cannabis producer Aurora Cannabis (NYSE: ACB) and big biotech Gilead Sciences (NASDAQ: GILD) mentioned in the same sentence, this will be a first for you. That's the range Constellation Brands (NYSE: STZ) used in estimating the potential for Canopy Growth (NYSE: CGC) before investing $4 b... | If you've never heard Canadian cannabis producer Aurora Cannabis (NYSE: ACB) and big biotech Gilead Sciences (NASDAQ: GILD) mentioned in the same sentence, this will be a first for you. Aurora estimates that medical cannabis outside of Canada presents a potential market of more than $50 billion of the total, while the ... | If you've never heard Canadian cannabis producer Aurora Cannabis (NYSE: ACB) and big biotech Gilead Sciences (NASDAQ: GILD) mentioned in the same sentence, this will be a first for you. Aurora estimates that medical cannabis outside of Canada presents a potential market of more than $50 billion of the total, while the ... |
38351.0 | 2019-06-16 00:00:00 UTC | 4 of the 14 Most Widely Held Stocks on Investing App Robinhood Are Marijuana Stocks | ACB | https://www.nasdaq.com/articles/4-of-the-14-most-widely-held-stocks-on-investing-app-robinhood-are-marijuana-stocks-2019 | nan | nan | In case you haven't noticed, marijuana stocks have the full and undivided attention of Wall Street and investors. A projected four- to sixfold increase in worldwide cannabis sales over the next decade, coupled with triple- or quadruple-digit percentage gains in popular pot stocks over the past couple of years, is gener... | Courtesy of a top-20 holdings list provided by Robinhood to Investor's Business Daily, these cannabis stocks are: Aurora Cannabis (NYSE: ACB): The No. Millennials really love pot stocks In Gallup's October 2018 survey on marijuana, the national pollster found that 66% of Americans favored the idea of broad-based legali... | Courtesy of a top-20 holdings list provided by Robinhood to Investor's Business Daily, these cannabis stocks are: Aurora Cannabis (NYSE: ACB): The No. Respectively, and not including joint venture and royalty company output, this ranks Aurora, Canopy, HEXO, and Cronos as Canada's No. All four -- Aurora, Cronos, Canopy,... | Courtesy of a top-20 holdings list provided by Robinhood to Investor's Business Daily, these cannabis stocks are: Aurora Cannabis (NYSE: ACB): The No. All four -- Aurora, Cronos, Canopy, and HEXO -- are currently losing money, and, with the exception of HEXO, may lose money again in 2020. As a result, Aurora Cannabis h... | Courtesy of a top-20 holdings list provided by Robinhood to Investor's Business Daily, these cannabis stocks are: Aurora Cannabis (NYSE: ACB): The No. Why Aurora, Cronos, Canopy, and HEXO are favorites among millennial investors Why these four names? Respectively, and not including joint venture and royalty company out... |
38352.0 | 2019-06-15 00:00:00 UTC | A No-Nonsense Look at Aurora Cannabis' Bottom Line | ACB | https://www.nasdaq.com/articles/a-no-nonsense-look-at-aurora-cannabis-bottom-line-2019-06-15 | nan | nan | It's no secret that the marijuana industry is pretty much the hottest thing on Wall Street right now, and with a few small exceptions (e.g., cryptocurrency and blockchain), it's been that way for the better part of three years.
The allure of cannabis is that the market is proven. There are tens of billions of dollars i... | Millennials have fallen head over heels for Aurora Cannabis If the cannabis industry were a popularity contest, Aurora Cannabis (NYSE: ACB) would be at the head of the pack among marijuana stocks. It's no secret that the marijuana industry is pretty much the hottest thing on Wall Street right now, and with a few small ... | Millennials have fallen head over heels for Aurora Cannabis If the cannabis industry were a popularity contest, Aurora Cannabis (NYSE: ACB) would be at the head of the pack among marijuana stocks. You'll note that I've ignored the more than CA$16 million Aurora gained above-the-line as the result of fair-value adjustme... | Millennials have fallen head over heels for Aurora Cannabis If the cannabis industry were a popularity contest, Aurora Cannabis (NYSE: ACB) would be at the head of the pack among marijuana stocks. As for expenses, Aurora recorded the following: General and administrative: CA$50.79 million Sales and marketing: CA$16.32 ... | Millennials have fallen head over heels for Aurora Cannabis If the cannabis industry were a popularity contest, Aurora Cannabis (NYSE: ACB) would be at the head of the pack among marijuana stocks. Marijuana growers like Aurora are classified by Canada as agricultural growers, which under IFRS accounting creates an odd ... |
38353.0 | 2019-06-14 00:00:00 UTC | 3 Medical Marijuana Stocks to Buy | ACB | https://www.nasdaq.com/articles/3-medical-marijuana-stocks-to-buy-2019-06-14 | nan | nan | [Editor’s note: This story was previously published in March 2019. It has since been updated and republished.]
Often, when analysts or bloggers talk up the potential of , the focus is on the consumer side of the industry. But some of the best stocks in the pot sector may be medical marijuana stocks.
Indeed, it’s on the... | InvestorPlace’s Matt McCall named CWBHF (the stock also trades on the Canadian Securities Exchange, ticker CWEB) as for 2019. The combination of Altria’s advertising and distribution reach and Cronos’ production capabilities would seem to be the best fit for the consumer side of the business. Admittedly, uplisting hasn... | Source: Shutterstock Charlotte’s Web (CWBHF) Charlotte’s Web (OTCMKTS:) has become one of the leading players in CBD oil (cannabidiol). Source: Shutterstock Cronos (CRON) Of late, marijuana producer Cronos Group (NASDAQ:) has made the headlines for its consumer business. And its established leadership in the Canadian m... | But some of the best stocks in the pot sector may be medical marijuana stocks. But for investors who see medical marijuana stocks as the next big thing, these three are the best stocks to buy for investors enamored with weed. But investors can’t ignore that Cronos is a medical marijuana stock as well. | But some of the best stocks in the pot sector may be medical marijuana stocks. But investors can’t ignore that Cronos is a medical marijuana stock as well. And its established leadership in the Canadian medical marijuana industry should drive consistent growth and allow CannTrust to stay profitable. |
38354.0 | 2019-06-13 00:00:00 UTC | Cronos Group Stock Is Just Getting Started | ACB | https://www.nasdaq.com/articles/cronos-group-stock-just-getting-started-2019-06-13 | nan | nan | The long-term prospects for Cronos Group (NASDAQ:) stock look good. That is, if you ask CRON stock fans. There is almost no convincing them otherwise. Critics of Cronos Group stock and the whole industry can offer smartest arguments to prove that the cannabis stocks are headed for disaster, but it will all fall on deaf... | Source: Shutterstock The bullish thesis for the industry is so vague and the scope is so widespread that it’s almost impossible to kill it this year. One thing is for sure, pot stocks make for great short-term trading vehicles so CRON has opportunities on both the upside and downside. Mid term, I favor the upside poten... | The long-term prospects for Cronos Group (NASDAQ:) stock look good. Earlier I mentioned that there are shorter- term time frames to trade. I also noted that the $14 per share zone is a long term pivot, but so is $16. | Critics of Cronos Group stock and the whole industry can offer smartest arguments to prove that the cannabis stocks are headed for disaster, but it will all fall on deaf ears. Trading CRON Stock So do I go all in on CRON? Mid term, I favor the upside potential through the rest of the year for CRON stock because it esta... | CRON is up 64% year-to-date — leading the pot stock pack. I also noted that the $14 per share zone is a long term pivot, but so is $16. So what are the bears shorting? |
38355.0 | 2019-06-12 00:00:00 UTC | 10 Numbers to Focus On When Canopy Growth Reports Its Fourth-Quarter Results | ACB | https://www.nasdaq.com/articles/10-numbers-focus-when-canopy-growth-reports-its-fourth-quarter-results-2019-06-12 | nan | nan | Sure, earnings season may have passed for the lion's share of brand-name companies, but that doesn't mean earnings reports cease altogether. Next week, the biggest name in all of cannabis, Canopy Growth (NYSE: CGC), will be dishing on its performance in the fourth quarter and full year of fiscal 2019.
According to a co... | Recreational sales as a percentage of total cannabis sales Whereas Canopy's primary rival, Aurora Cannabis (NYSE: ACB), has decided to focus its attention on the medical marijuana community (Aurora generates half its cannabis sales from medical pot), Canopy Growth's initial quarter of recreational marijuana sales in th... | Recreational sales as a percentage of total cannabis sales Whereas Canopy's primary rival, Aurora Cannabis (NYSE: ACB), has decided to focus its attention on the medical marijuana community (Aurora generates half its cannabis sales from medical pot), Canopy Growth's initial quarter of recreational marijuana sales in th... | Recreational sales as a percentage of total cannabis sales Whereas Canopy's primary rival, Aurora Cannabis (NYSE: ACB), has decided to focus its attention on the medical marijuana community (Aurora generates half its cannabis sales from medical pot), Canopy Growth's initial quarter of recreational marijuana sales in th... | Recreational sales as a percentage of total cannabis sales Whereas Canopy's primary rival, Aurora Cannabis (NYSE: ACB), has decided to focus its attention on the medical marijuana community (Aurora generates half its cannabis sales from medical pot), Canopy Growth's initial quarter of recreational marijuana sales in th... |
38356.0 | 2019-06-12 00:00:00 UTC | Vape Giant PAX Labs Picked 4 Popular Pot Stocks as Its Supply Partners | ACB | https://www.nasdaq.com/articles/vape-giant-pax-labs-picked-4-popular-pot-stocks-its-supply-partners-2019-06-12 | nan | nan | After hiding in the shadows for decades, the cannabis movement is experiencing a long-overdue coming-out party. Following the legalization of recreational marijuana in Canada, and the ongoing push to legalize at the state level in the U.S. and in various countries around the world, the potential for legal marijuana is ... | The four companies chosen to partner with PAX Labs were Aurora Cannabis (NYSE: ACB), Aphria (NYSE: APHA), OrganiGram Holdings (NASDAQ: OGI), and The Supreme Cannabis Company (NASDAQOTH: SPRWF). That's going to roll out the red (or should I say "green") carpet for these significantly higher-margin products, relative to ... | The four companies chosen to partner with PAX Labs were Aurora Cannabis (NYSE: ACB), Aphria (NYSE: APHA), OrganiGram Holdings (NASDAQ: OGI), and The Supreme Cannabis Company (NASDAQOTH: SPRWF). Vape giant PAX Labs chooses 4 top marijuana stocks to be its supply partners San Francisco-based, PAX Labs, a vaporizer powerh... | The four companies chosen to partner with PAX Labs were Aurora Cannabis (NYSE: ACB), Aphria (NYSE: APHA), OrganiGram Holdings (NASDAQ: OGI), and The Supreme Cannabis Company (NASDAQOTH: SPRWF). Vape giant PAX Labs chooses 4 top marijuana stocks to be its supply partners San Francisco-based, PAX Labs, a vaporizer powerh... | The four companies chosen to partner with PAX Labs were Aurora Cannabis (NYSE: ACB), Aphria (NYSE: APHA), OrganiGram Holdings (NASDAQ: OGI), and The Supreme Cannabis Company (NASDAQOTH: SPRWF). Here's why Aurora, Aphria, OrganiGram, and Supreme Cannabis are logical partners You're probably wondering why PAX Labs chose ... |
38357.0 | 2019-06-11 00:00:00 UTC | Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder | ACB | https://www.nasdaq.com/articles/zynerba-stock-soars-cannabidiol-patent-autism-spectrum-disorder-2019-06-11 | nan | nan | Shares of Zynerba Pharmaceuticals (NASDAQ:) are surging Tuesday after the company landed a patent for the treatment of autism spectrum disorder. Specifically, the patent covers treatment using cannabidiol, which will surely add a spark to ZYNE stock.
Source:
The stock was up 8% in pre-market trading and there’s potenti... | Shares of Zynerba Pharmaceuticals (NASDAQ:) are surging Tuesday after the company landed a patent for the treatment of autism spectrum disorder. The Patent Zynerba is building out a portfolio of different treatments based around its potential cannabidiol product Zygel. The patented treatment “ claims directed to method... | Shares of Zynerba Pharmaceuticals (NASDAQ:) are surging Tuesday after the company landed a patent for the treatment of autism spectrum disorder. In the same light, it’s not even a well-known cannabis stock, like Canopy Growth (NYSE:) or Aurora Cannabis (NYSE:). 10,314,792, which is titled, “Treatment of Autism Spectrum... | So if the treatment is successful, ZYNE stock will have the rights to this treatment for almost two decades. The patented treatment “ claims directed to methods of treating autism spectrum disorder by administering a therapeutically effective amount of synthetic cannabidiol.” It was granted during the enrollment period... | Shares of Zynerba Pharmaceuticals (NASDAQ:) are surging Tuesday after the company landed a patent for the treatment of autism spectrum disorder. Trading ZYNE Stock The big boost in ZYNE stock comes as little surprise. That said, it would be highly discouraging to see ZYNE stock lose all of Tuesday’s gains. |
38358.0 | 2019-06-11 00:00:00 UTC | Here’s What Needs to Happen for Aurora Stock to Break Out | ACB | https://www.nasdaq.com/articles/heres-what-needs-happen-aurora-stock-break-out-2019-06-11 | nan | nan | Despite the market’s hearty rally last week wasn’t a good one for Aurora Cannabis (NYSE:) because Aurora stock is stuck in a technical downtrend.
Source: Shutterstock
Even as a number of stocks in the cannabis industry were bouncing higher as well, the recent underperformance vs. the overall market has investors wonder... | that Aurora’s “international medical-use growth opportunities are limited outside of Canada and Germany.” They remain cautious as ACB due to execution concerns and the company’s “lack of definitive strategy.” So what do the charts say? ACB stock commands a market cap of almost $8 billion, while full-year estimates for ... | Trading ACB Stock Shares of Aurora stock are stuck in a tough downtrend (blue lines), with channel resistance squeezing it lower. They slapped a hold rating and a C$10 price target on ACB ($7.47 USD). that Aurora’s “international medical-use growth opportunities are limited outside of Canada and Germany.” They remain c... | Trading ACB Stock Shares of Aurora stock are stuck in a tough downtrend (blue lines), with channel resistance squeezing it lower. They slapped a hold rating and a C$10 price target on ACB ($7.47 USD). that Aurora’s “international medical-use growth opportunities are limited outside of Canada and Germany.” They remain c... | Trading ACB Stock Shares of Aurora stock are stuck in a tough downtrend (blue lines), with channel resistance squeezing it lower. They slapped a hold rating and a C$10 price target on ACB ($7.47 USD). that Aurora’s “international medical-use growth opportunities are limited outside of Canada and Germany.” They remain c... |
38359.0 | 2019-06-11 00:00:00 UTC | 3 Scenarios That Would Make Aurora Cannabis a Buy | ACB | https://www.nasdaq.com/articles/3-scenarios-would-make-aurora-cannabis-buy-2019-06-11 | nan | nan | Aurora Cannabis (NYSE: ACB) is the second-largest marijuana stock by market cap, is projected to lead all growers in peak annual output with at least 662,000 kilos, based on company estimates spanning its 14 grow farms, and has a more diverse combined production and distribution presence than any other cannabis grower.... | Aurora Cannabis (NYSE: ACB) is the second-largest marijuana stock by market cap, is projected to lead all growers in peak annual output with at least 662,000 kilos, based on company estimates spanning its 14 grow farms, and has a more diverse combined production and distribution presence than any other cannabis grower.... | Aurora Cannabis (NYSE: ACB) is the second-largest marijuana stock by market cap, is projected to lead all growers in peak annual output with at least 662,000 kilos, based on company estimates spanning its 14 grow farms, and has a more diverse combined production and distribution presence than any other cannabis grower.... | Aurora Cannabis (NYSE: ACB) is the second-largest marijuana stock by market cap, is projected to lead all growers in peak annual output with at least 662,000 kilos, based on company estimates spanning its 14 grow farms, and has a more diverse combined production and distribution presence than any other cannabis grower.... | Aurora Cannabis (NYSE: ACB) is the second-largest marijuana stock by market cap, is projected to lead all growers in peak annual output with at least 662,000 kilos, based on company estimates spanning its 14 grow farms, and has a more diverse combined production and distribution presence than any other cannabis grower.... |
38360.0 | 2019-06-10 00:00:00 UTC | Don't Expect CBD Action Anytime Soon | ACB | https://www.nasdaq.com/articles/dont-expect-cbd-action-anytime-soon-2019-06-10 | nan | nan | The recent public hearing by the Food & Drug Administration on cannabidiol (CBD) provided little clarity on the regulatory way forward for the marijuana-based compound. Acting FDA commissioner Ned Sharpless said there were "real risks" with using CBD and reiterated that since the agency has approved drugs with CBD as t... | Reducing the carnival barker atmosphere It doesn't help that some companies hawk CBD like snake oil, claiming magical, therapeutic properties that can relieve or cure a variety of ailments, from anxiety and inflammation to insomnia and pain, and have added it to all manner of products like creams, lotions, and ointment... | Acting FDA commissioner Ned Sharpless said there were "real risks" with using CBD and reiterated that since the agency has approved drugs with CBD as the active ingredient, it cannot be added to food products sold across state lines or sold as a dietary supplement. Sharpless is worried that wanton marketing of CBD prod... | Acting FDA commissioner Ned Sharpless said there were "real risks" with using CBD and reiterated that since the agency has approved drugs with CBD as the active ingredient, it cannot be added to food products sold across state lines or sold as a dietary supplement. While there are studies that back up the efficacy of C... | Acting FDA commissioner Ned Sharpless said there were "real risks" with using CBD and reiterated that since the agency has approved drugs with CBD as the active ingredient, it cannot be added to food products sold across state lines or sold as a dietary supplement. Sharpless is worried that wanton marketing of CBD prod... |
38361.0 | 2019-06-10 00:00:00 UTC | Hexo Stock May Be the Cannabis Industry’s Best-Kept Secret | ACB | https://www.nasdaq.com/articles/hexo-stock-may-be-cannabis-industrys-best-kept-secret-2019-06-10 | nan | nan | Though the bulk of cannabis stock-mania to date has focused on Canopy Growth (NYSE:), Tilray (NASDAQ:), Aurora Cannabis (NYSE:) and Cronos Group (NASDAQ:),arguably the most compelling pick in the bunch, Hexo (NYSEAMERICAN:), has been habitually overlooked.
That’s changing though, and for good reason. As marijuana-stoc... | As marijuana-stock mania continues to mature and investors are willing and able to start judging these companies on their individual merits, they’re finding HEXO is about as well-positioned for growth as any other name in the business. The overarching difference between HEXO and its peers, however, is its plans to pene... | Though the bulk of cannabis stock-mania to date has focused on Canopy Growth (NYSE:), Tilray (NASDAQ:), Aurora Cannabis (NYSE:) and Cronos Group (NASDAQ:),arguably the most compelling pick in the bunch, Hexo (NYSEAMERICAN:), has been habitually overlooked. Constellation Brands (NYSE:) and Canopy Growth are teaming up ... | Though the bulk of cannabis stock-mania to date has focused on Canopy Growth (NYSE:), Tilray (NASDAQ:), Aurora Cannabis (NYSE:) and Cronos Group (NASDAQ:),arguably the most compelling pick in the bunch, Hexo (NYSEAMERICAN:), has been habitually overlooked. Looking Ahead for Hexo Stock Bank of America’s Christopher Car... | It held discussions with Aurora Cannabis and Aphria (NYSE:) along with two other unnamed outfits, but Frederic Landtmeters, the CEO of Molson Coors Canada, ultimately concluded it was Hexo’s “track record of innovation” that would make it the highest-potential partner. What that future has in store remains unclear, par... |
38362.0 | 2019-06-10 00:00:00 UTC | Why Canopy, Aurora, and Aphria Stocks Fell up to 20% in May -- and How They're Faring in June | ACB | https://www.nasdaq.com/articles/why-canopy-aurora-and-aphria-stocks-fell-20-may-and-how-theyre-faring-june-2019-06-10 | nan | nan | What happened
Along with nearly all cannabis stocks, Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), and Aphria (NYSE: APHA) cratered last month. Stocks of these three top Canadian growers plunged 20.3%, 16.4%, and 13.6%, respectively, according to data from S&P Global Market Intelligence.
(A cannabis player th... | What happened Along with nearly all cannabis stocks, Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), and Aphria (NYSE: APHA) cratered last month. (Update: June has seen an easing of trade tensions, with Trump announcing on Friday that he was suspending the tariffs on Mexican goods after Mexico agreed to strengt... | What happened Along with nearly all cannabis stocks, Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), and Aphria (NYSE: APHA) cratered last month. As is rather typical for such pullbacks, high-flying, highly valued stocks were hit the hardest -- and no sector has recently experienced stock prices and valuations ... | What happened Along with nearly all cannabis stocks, Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), and Aphria (NYSE: APHA) cratered last month. Because it is the largest stock in the cannabis sector by market cap, Canopy's quarterly results and management's outlook should not only move its stock, but also imp... | What happened Along with nearly all cannabis stocks, Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ACB), and Aphria (NYSE: APHA) cratered last month. (Update: June has seen an easing of trade tensions, with Trump announcing on Friday that he was suspending the tariffs on Mexican goods after Mexico agreed to strengt... |
38363.0 | 2019-06-10 00:00:00 UTC | This Wall Street Firm Advises Pumping the Brakes on Aurora Cannabis | ACB | https://www.nasdaq.com/articles/wall-street-firm-advises-pumping-brakes-aurora-cannabis-2019-06-10 | nan | nan | Over the past couple of years, no industry has had investors seeing green quite like the legal cannabis industry. Some of the most popular pot stocks, including Aurora Cannabis (NYSE: ACB), Canopy Growth, and Cronos Group, have advanced by a quadruple-digit percentage since the beginning of 2016, on the expectation of ... | Some of the most popular pot stocks, including Aurora Cannabis (NYSE: ACB), Canopy Growth, and Cronos Group, have advanced by a quadruple-digit percentage since the beginning of 2016, on the expectation of rapid but long-term sales growth. Meanwhile, Christopher Carey at Bank of America anointed a buy rating on Aurora ... | Some of the most popular pot stocks, including Aurora Cannabis (NYSE: ACB), Canopy Growth, and Cronos Group, have advanced by a quadruple-digit percentage since the beginning of 2016, on the expectation of rapid but long-term sales growth. Covering analyst W. Andrew Carter, who prefers Canopy Growth as the top industry... | Some of the most popular pot stocks, including Aurora Cannabis (NYSE: ACB), Canopy Growth, and Cronos Group, have advanced by a quadruple-digit percentage since the beginning of 2016, on the expectation of rapid but long-term sales growth. This Wall Street firm is wary of the most popular pot stock Projected leading pr... | Some of the most popular pot stocks, including Aurora Cannabis (NYSE: ACB), Canopy Growth, and Cronos Group, have advanced by a quadruple-digit percentage since the beginning of 2016, on the expectation of rapid but long-term sales growth. Generally speaking, Wall Street views Aurora Cannabis very favorably, but one fi... |
38364.0 | 2019-06-10 00:00:00 UTC | Amid Change, Things Stay The Same For New Age Beverages Stock | ACB | https://www.nasdaq.com/articles/amid-change-things-stay-same-new-age-beverages-stock-2019-06-10 | nan | nan | In recent weeks, New Age Beverages (NASDAQ:) has deeply expanded its reach. It has attracted a key retailer and acquired new products as well as a distribution network. However, NBEV stock continues to fall despite these developments. The shares are down more than 14% in the last month, compared to the S&P 500 index, w... | While these deals show progress in one sense, NBEV will remain a high-risk play until it can deliver results in the CBD-infused beverage market. They happen to distribute well-known brands such as Nestea, Illy ready-to-drink coffee beverages, and Evian water. Without a doubt, the Walmart deal and the Brands Within Reac... | Deals Bring Benefits and Challenges The deal to bring its Marley+CBD Mellow Mood into Walmart (NYSE:) stores carries with it both opportunity and risk. These multi-billion dollar companies have the needed resources to outspend this much smaller $325 million New Age Beverages, How NBEV stock holds up when these companie... | However, becoming more of a beverage company makes NBEV stock arguably less of a “marijuana equity.” Hence, it could struggle more to attract the outsized multiples of a Canopy Growth (NYSE:) or Aurora Cannabis (NYSE:). These multi-billion dollar companies have the needed resources to outspend this much smaller $325 mi... | Deals Bring Benefits and Challenges The deal to bring its Marley+CBD Mellow Mood into Walmart (NYSE:) stores carries with it both opportunity and risk. Little’s Changed for NBEV Stock Even more than that is the viability of NBEV stock itself. This possibility makes NBEV stock a speculative play if nothing else. |
38365.0 | 2019-06-09 00:00:00 UTC | Where Will Aurora Cannabis Be in 10 Years? | ACB | https://www.nasdaq.com/articles/where-will-aurora-cannabis-be-10-years-2019-06-09 | nan | nan | In less than six years, Aurora Cannabis (NYSE: ACB) has built a cannabis empire. It's an empire that stretches across five continents to 24 countries. Aurora now claims the highest production capacity in the entire cannabis industry. And the company's sales are growing by 21% -- not year over year but quarter over quar... | In less than six years, Aurora Cannabis (NYSE: ACB) has built a cannabis empire. I'll be surprised if tobacco giant Altria (NYSE: MO) doesn't fully gobble up Cronos Group (NASDAQ: CRON) down the road. My hunch, though, is that we'll see Aurora make some deals in the not-too-distant future with big U.S. companies that p... | In less than six years, Aurora Cannabis (NYSE: ACB) has built a cannabis empire. That makes sense considering the company is one of the biggest cannabis producers in terms of production capacity, market cap, and sales. Cannabis market researcher Brightfield Group projects that the European medical cannabis and cannabid... | In less than six years, Aurora Cannabis (NYSE: ACB) has built a cannabis empire. I think that Aurora will be the top cannabis company in a fast-growing European cannabis market. Cannabis market researcher Brightfield Group projects that the European medical cannabis and cannabidiol (CBD) market will soar to nearly $8 b... | In less than six years, Aurora Cannabis (NYSE: ACB) has built a cannabis empire. But that's where Aurora has been and is now. Where will the company be in 10 years? |
38366.0 | 2019-06-09 00:00:00 UTC | Better Buy: Aurora Cannabis vs. Scotts Miracle-Gro Company | ACB | https://www.nasdaq.com/articles/better-buy%3A-aurora-cannabis-vs.-scotts-miracle-gro-company-2019-06-09 | nan | nan | It's been a great year for Aurora Cannabis (NYSE: ACB) and Scotts Miracle-Gro Company (NYSE: SMG) so far. Both stocks are up more than 50% year to date.
How the stocks achieved those gains have been quite different, though. Aurora's share price doubled by mid-March before falling back down to earth a bit. Scotts, mean... | It's been a great year for Aurora Cannabis (NYSE: ACB) and Scotts Miracle-Gro Company (NYSE: SMG) so far. Aurora's acquisitions of HempCo, AgroPro, Borela, and ICC Labs give it an unmatched scope of operations in producing and processing hemp products. It brought billionaire investor Nelson Peltz on board as a strategi... | It's been a great year for Aurora Cannabis (NYSE: ACB) and Scotts Miracle-Gro Company (NYSE: SMG) so far. While the cannabis market definitely presents great growth prospects for Scotts Miracle-Gro, consumer lawn and garden products still generate most of the company's revenue. In addition to these growth opportunities... | It's been a great year for Aurora Cannabis (NYSE: ACB) and Scotts Miracle-Gro Company (NYSE: SMG) so far. The case for Aurora Cannabis Any discussion about the merits of investing in Aurora Cannabis has to include the company's industry-leading capacity. The case for Scotts Miracle-Gro Scotts Miracle-Gro set out a few ... | It's been a great year for Aurora Cannabis (NYSE: ACB) and Scotts Miracle-Gro Company (NYSE: SMG) so far. The case for Scotts Miracle-Gro Scotts Miracle-Gro set out a few years ago to become the leader in supplying key products needed by the cannabis industry, including hydroponics, lighting systems, and ventilation sy... |
38367.0 | 2019-06-07 00:00:00 UTC | Aurora Stock Slips, But Volatility Doesn’t Mean 2019 Growth Is Over | ACB | https://www.nasdaq.com/articles/aurora-stock-slips-volatility-doesnt-mean-2019-growth-over-2019-06-07 | nan | nan | Investors who follow marijuana stocks noted two Canadian companies whose tickers were moving in opposite directions Wednesday. Cronos Group (NASDAQ:) notched an impressive 10.9% gain, while Aurora Cannabis (NYSE:ACB) was down 1.8% on the day. Cronos investors celebrated, but if you have ACB stock in your portfolio, the... | ACB stock hit all-time highs (no pun intended) last October as investors rushed to get onboard in the months after Canada legalized recreational marijuana, with anticipation that multiple states were on the verge of doing the same as a part of midterm election ballots. Cronos Group (NASDAQ:) notched an impressive 10.9%... | ACB stock hit all-time highs (no pun intended) last October as investors rushed to get onboard in the months after Canada legalized recreational marijuana, with anticipation that multiple states were on the verge of doing the same as a part of midterm election ballots. Cronos Group (NASDAQ:) notched an impressive 10.9%... | ACB stock hit all-time highs (no pun intended) last October as investors rushed to get onboard in the months after Canada legalized recreational marijuana, with anticipation that multiple states were on the verge of doing the same as a part of midterm election ballots. Cronos Group (NASDAQ:) notched an impressive 10.9%... | Cronos Group (NASDAQ:) notched an impressive 10.9% gain, while Aurora Cannabis (NYSE:ACB) was down 1.8% on the day. Cronos investors celebrated, but if you have ACB stock in your portfolio, there’s no need for panic. That being said, yesterday’s close of $7.53 is a long way off from last fall, when ACB stock nearly hit... |
38368.0 | 2019-06-07 00:00:00 UTC | Every Popular Pot Stock Is Now in Bear Market Territory | ACB | https://www.nasdaq.com/articles/every-popular-pot-stock-now-bear-market-territory-2019-06-07 | nan | nan | In many ways, the legal marijuana industry is viewed as a once-in-a-generation, or perhaps once-in-a-lifetime, growth opportunity. With tens of billions of dollars in sales regularly occurring in the black market, gradually moving these transactions over to legal channels could produce substantial ripples within the ca... | Here's a brief rundown of how the most popular Canadian marijuana stocks have performed since hitting their all-time highs, courtesy of YCharts (through June 3): HEXO (NYSEMKT: HEXO): Down 25% Canopy Growth (NYSE: CGC): Down 32% Aurora Cannabis (NYSE: ACB): Down 39% Cronos Group (NASDAQ: CRON): Down 42% Aphria (NYSE: A... | Here's a brief rundown of how the most popular Canadian marijuana stocks have performed since hitting their all-time highs, courtesy of YCharts (through June 3): HEXO (NYSEMKT: HEXO): Down 25% Canopy Growth (NYSE: CGC): Down 32% Aurora Cannabis (NYSE: ACB): Down 39% Cronos Group (NASDAQ: CRON): Down 42% Aphria (NYSE: A... | Here's a brief rundown of how the most popular Canadian marijuana stocks have performed since hitting their all-time highs, courtesy of YCharts (through June 3): HEXO (NYSEMKT: HEXO): Down 25% Canopy Growth (NYSE: CGC): Down 32% Aurora Cannabis (NYSE: ACB): Down 39% Cronos Group (NASDAQ: CRON): Down 42% Aphria (NYSE: A... | Here's a brief rundown of how the most popular Canadian marijuana stocks have performed since hitting their all-time highs, courtesy of YCharts (through June 3): HEXO (NYSEMKT: HEXO): Down 25% Canopy Growth (NYSE: CGC): Down 32% Aurora Cannabis (NYSE: ACB): Down 39% Cronos Group (NASDAQ: CRON): Down 42% Aphria (NYSE: A... |
38369.0 | 2019-06-06 00:00:00 UTC | Aphria Stock Could Deliver Massive Gains | ACB | https://www.nasdaq.com/articles/aphria-stock-could-deliver-massive-gains-2019-06-06 | nan | nan | After the fluctuations of marijuana stocks over the last year, Aphria (NYSE:) stock still trades more than 50% below its 52-week high. Investors sold off Aphria stock, as many questioned whether APHA was a “shell game”after it bought assets in Latin America.
However, the executives who drove that purchase have left Aph... | Investors sold off Aphria stock, as many questioned whether APHA was a “shell game”after it bought assets in Latin America. New Management Leaves APHA Well-Positioned for Growth As a result of the sharp decline of Aphria stock, founders Vic Neufeld and Cole Cacciavillani left the company. In addition to its assets in L... | After the fluctuations of marijuana stocks over the last year, Aphria (NYSE:) stock still trades more than 50% below its 52-week high. However, most marijuana stocks sold off after Canada legalized cannabis. Final Thoughts on Aphria Stock If APHA can restore its reputation, Aphria stock could rise tremendously. | Aphria Inc dropped further when it as a “shell game with a cannabis business on the side.” Aphria stock fell briefly below $5 per share following Hindenburg’s statement. Final Thoughts on Aphria Stock If APHA can restore its reputation, Aphria stock could rise tremendously. If APHA’s multiple expands to levels that are... | During his time at Hain, Simon built a reputation for growing companies. However, Simon is 60 years old and was given the title of interim CEO. Also, since it operates in an industry with triple-digit price-sales ratios, the multiple of APHA stock can surge tremendously. |
38370.0 | 2019-06-06 00:00:00 UTC | 3 Pot Stocks to Avoid Like the Plague in June | ACB | https://www.nasdaq.com/articles/3-pot-stocks-avoid-plague-june-2019-06-06 | nan | nan | After months of sizzling gains, marijuana stocks cooled off in a big way in May. The Horizons Marijuana Life Sciences ETF, the first tradable cannabis ETF that holds more than four dozen pot stocks of various weightings, fell by more than 13% in May after having tripled the S&P 500's return through the first four month... | There's no denying that Aurora Cannabis (NYSE: ACB) looks to be the clear cannabis production leader in Canada. Yes, California has had supply chain issues of its own, but this was unexpectedly slow growth in a state that's expected to surpass Canada in terms of total annual marijuana revenue. While there are aspects o... | There's no denying that Aurora Cannabis (NYSE: ACB) looks to be the clear cannabis production leader in Canada. Yes, management expects recurring EBITDA to become positive in the fiscal fourth quarter (April-June 2019), but positive EBITDA doesn't mean profitability. MedMen Enterprises In April, shortly after upscale v... | There's no denying that Aurora Cannabis (NYSE: ACB) looks to be the clear cannabis production leader in Canada. Tilray Lastly, ambitious pot stock investors should avoid thinking that the recent dip in Tilray (NASDAQ: TLRY) stock is a buying opportunity. If Tilray had a clear game plan, it wouldn't be a buy, but it als... | There's no denying that Aurora Cannabis (NYSE: ACB) looks to be the clear cannabis production leader in Canada. Total expenses more than tripled year over year to $73 million, with operating losses for the first nine months of fiscal 2019 hitting $178.4 million. However, the Tilray investors know today looks very littl... |
38371.0 | 2019-06-05 00:00:00 UTC | Aurora Cannabis Stock Is a (Pot) Growth Story | ACB | https://www.nasdaq.com/articles/aurora-cannabis-stock-pot-growth-story-2019-06-05 | nan | nan | Every marijuana stock has a different strategy. For Aurora Cannabis (NYSE:) stock, the strategy is simple. Grow a lot of pot, then find cheap ways to promote it.
Source: Shutterstock
This strategy has led to something very unusual for a marijuana stock last fall — a profit. It was a small profit, and it was short-lived... | The Grow Light is On for ACB Stock Aurora expects to grow 662,000 kilograms of Canadian marijuana next year and has the capacity to grow . Just like tech stocks, marijuana companies that are serious about becoming market leaders must raise money, take losses and look over the horizon to profit. Aurora’s latest loss, (... | The Grow Light is On for ACB Stock Aurora expects to grow 662,000 kilograms of Canadian marijuana next year and has the capacity to grow . That’s because legal pot, a market that opened last year in Canada and is now opening state-by-state in the U.S. (Illinois joined the parade ), is a fast-growing market that require... | The Grow Light is On for ACB Stock Aurora expects to grow 662,000 kilograms of Canadian marijuana next year and has the capacity to grow . Just like tech stocks, marijuana companies that are serious about becoming market leaders must raise money, take losses and look over the horizon to profit. The U.S. Market Aurora s... | The Grow Light is On for ACB Stock Aurora expects to grow 662,000 kilograms of Canadian marijuana next year and has the capacity to grow . Every marijuana stock has a different strategy. Grow a lot of pot, then find cheap ways to promote it. |
38372.0 | 2019-06-05 00:00:00 UTC | Marijuana Massacre: These 35 Pot Stocks Fell at Least 10% in May | ACB | https://www.nasdaq.com/articles/marijuana-massacre%3A-these-35-pot-stocks-fell-least-10-may-2019-06-05 | nan | nan | Throughout most of 2019, marijuana stocks have been virtually unstoppable. In the first quarter alone, the first-ever cannabis exchange-traded fund, the Horizons Marijuana Life Sciences ETF, advanced by more than 50%, with 14 prominent pot stocks gaining at least 70% through March. Although gains slowed a bit in April,... | Insys Therapeutics: Down 82% TILT Holdings: Down 36% Charlotte's Web Holdings (NASDAQOTH: CWBHF): Down 32% Tilray (NASDAQ: TLRY): Down 26% Harvest Health & Recreation: Down 23% Green Growth Brands: Down 23% The Green Organic Dutchman: Down 22% CannTrust Holdings (NYSE: CTST): Down 22% KushCo Holdings: Down 22% VIVO Can... | Insys Therapeutics: Down 82% TILT Holdings: Down 36% Charlotte's Web Holdings (NASDAQOTH: CWBHF): Down 32% Tilray (NASDAQ: TLRY): Down 26% Harvest Health & Recreation: Down 23% Green Growth Brands: Down 23% The Green Organic Dutchman: Down 22% CannTrust Holdings (NYSE: CTST): Down 22% KushCo Holdings: Down 22% VIVO Can... | Insys Therapeutics: Down 82% TILT Holdings: Down 36% Charlotte's Web Holdings (NASDAQOTH: CWBHF): Down 32% Tilray (NASDAQ: TLRY): Down 26% Harvest Health & Recreation: Down 23% Green Growth Brands: Down 23% The Green Organic Dutchman: Down 22% CannTrust Holdings (NYSE: CTST): Down 22% KushCo Holdings: Down 22% VIVO Can... | Insys Therapeutics: Down 82% TILT Holdings: Down 36% Charlotte's Web Holdings (NASDAQOTH: CWBHF): Down 32% Tilray (NASDAQ: TLRY): Down 26% Harvest Health & Recreation: Down 23% Green Growth Brands: Down 23% The Green Organic Dutchman: Down 22% CannTrust Holdings (NYSE: CTST): Down 22% KushCo Holdings: Down 22% VIVO Can... |
38373.0 | 2019-06-05 00:00:00 UTC | 5 Cannabis Industry Myths That Aurora Cannabis Wants to Clear Up | ACB | https://www.nasdaq.com/articles/5-cannabis-industry-myths-aurora-cannabis-wants-clear-2019-06-05 | nan | nan | Aurora Cannabis (NYSE: ACB) claims the largest funded production capacity among Canadian cannabis producers. It's the second-largest cannabis producer in the world in terms of market cap, and operates in 24 countries spanning five continents. It's probably fair to say that the Aurora executives have expertise in the ca... | Aurora Cannabis (NYSE: ACB) claims the largest funded production capacity among Canadian cannabis producers. Lakmaaker mentioned that Aurora CEO Terry Booth likes to say that the thing that keeps him up at night is not being able to supply enough product to meet the growing demand globally. He noted that there are sign... | Aurora Cannabis (NYSE: ACB) claims the largest funded production capacity among Canadian cannabis producers. Canadian medical cannabis isn't a growth market Many people assumed that the Canadian medical cannabis market would be flat at best or even decline following the legalization of adult-use recreational marijuana.... | Aurora Cannabis (NYSE: ACB) claims the largest funded production capacity among Canadian cannabis producers. Canadian medical cannabis isn't a growth market Many people assumed that the Canadian medical cannabis market would be flat at best or even decline following the legalization of adult-use recreational marijuana.... | Aurora Cannabis (NYSE: ACB) claims the largest funded production capacity among Canadian cannabis producers. Canadian medical cannabis isn't a growth market Many people assumed that the Canadian medical cannabis market would be flat at best or even decline following the legalization of adult-use recreational marijuana.... |
38374.0 | 2019-06-04 00:00:00 UTC | What Now for Aurora Cannabis Stock and Other Cannabis Plays? | ACB | https://www.nasdaq.com/articles/what-now-aurora-cannabis-stock-and-other-cannabis-plays-2019-06-04 | nan | nan | Cannabis stocks like Aurora Cannabis (NYSE:) are struggling at the moment. ACB stock is up over 50% so far this year, but it has dropped nearly 30% from its March highs. Whether the weakness is being caused by concerns about the stock market or a lack of patience, Aurora stock isn’t the only cannabis stock that’s heade... | The new Farm Bill led to optimism late last year, but hemp alone isn’t moving the needle for ACB stock and its $7 billion-plus market capitalization. ACB stock is up over 50% so far this year, but it has dropped nearly 30% from its March highs. It wasn’t enough, however: ACB stock fell on the news and has continued to ... | Be Careful With Aurora Cannabis Stock Unsurprisingly, cannabis stocks have been very volatile recently, and ACB stock has been no exception. ACB stock is up over 50% so far this year, but it has dropped nearly 30% from its March highs. It wasn’t enough, however: ACB stock fell on the news and has continued to drop. | Be Careful With Aurora Cannabis Stock Unsurprisingly, cannabis stocks have been very volatile recently, and ACB stock has been no exception. ACB stock is up over 50% so far this year, but it has dropped nearly 30% from its March highs. It wasn’t enough, however: ACB stock fell on the news and has continued to drop. | ACB stock is up over 50% so far this year, but it has dropped nearly 30% from its March highs. It wasn’t enough, however: ACB stock fell on the news and has continued to drop. The problem for ACB stock, and for the space as a whole, seems reasonably simple: investors are trying to figure out what’s next. |
38375.0 | 2019-06-04 00:00:00 UTC | FDA Hearing Won’t Hurt Canopy’s Growth, But It Could Hit CGC Stock | ACB | https://www.nasdaq.com/articles/fda-hearing-wont-hurt-canopys-growth-it-could-hit-cgc-stock-2019-06-04 | nan | nan | Like many cannabis stocks, Canopy Growth (NYSE:) fell in Monday trading due to an FDA meeting on CBD. Marijuana stocks fell as speakers at this inquiry offered conflicting views of the marijuana industry. Although the hearing will likely not stop the march toward eventual legal status, it could motivate investors to ca... | Although the hearing will likely not stop the march toward eventual legal status, it could motivate investors to call the valuation of CGC stock into question. More than 100 speakers offered their views on the substance, with researchers, health professionals, supporters, opponents and growers among those who spoke to ... | Like many cannabis stocks, Canopy Growth (NYSE:) fell in Monday trading due to an FDA meeting on CBD. CGC stock and other marijuana equities fell as speakers spoke of minimal standardization and a possible lack of concern about safety or effectiveness. CGC remains the leading cannabis company and demand remains high. | Between Canopy Growth’s size, its hemp production in New York State, and now, the option to buy Acreage Holdings (OTCMKTS:), CGC should emerge as the leading marijuana company once weed becomes legal in the U.S. CGC Stock May Suffer Even If Canopy Prospers Nonetheless, this may not translate into gains for Canopy Growt... | Like many cannabis stocks, Canopy Growth (NYSE:) fell in Monday trading due to an FDA meeting on CBD. Canopy’s Growth Will See Few Effects I think this changes little for Canopy. The Bottom Line on CGC Stock The FDA hearings will likely not affect the trend toward legalization, but it could cast doubts upon the valuati... |
38376.0 | 2019-06-04 00:00:00 UTC | Dip in Shares of Aurora Cannabis Creates an Opportunity | ACB | https://www.nasdaq.com/articles/dip-shares-aurora-cannabis-creates-opportunity-2019-06-04 | nan | nan | Investors should brace for the steady decline in cannabis stocks to continue in the near term. So long as stock markets decline, fueled by tensions between the U.S. and China, markets will have little appetite for risk. Those include companies that are spending to expand but are not yet profitable yet. The FDA’s public... | With the ~14% drop in the stock price in the last week and an 18.5% drop in the last month, traders who missed the rally may look at ACB stock again. Its stock price is trending downward today but could quickly reverse if the company’s sales drive EBITDA profitability next quarter. With very strong demand in the countr... | With the ~14% drop in the stock price in the last week and an 18.5% drop in the last month, traders who missed the rally may look at ACB stock again. Getting to EBITDA-positive numbers will depend on net selling prices holding above at least the $6 level. Looking ahead, when extraction capacity increases, extract sales... | With the ~14% drop in the stock price in the last week and an 18.5% drop in the last month, traders who missed the rally may look at ACB stock again. Still, investors might want to wait for the company to report positive EBITDA results before taking too big a position in Aurora stock. Aurora Cannabis Increasing Product... | With the ~14% drop in the stock price in the last week and an 18.5% drop in the last month, traders who missed the rally may look at ACB stock again. Getting to EBITDA-positive numbers will depend on net selling prices holding above at least the $6 level. At that level, traders could start another position and hold the... |
38377.0 | 2019-06-04 00:00:00 UTC | 3 Top Stocks Under $20 | ACB | https://www.nasdaq.com/articles/3-top-stocks-under-%2420-2019-06-04 | nan | nan | A low-price stock can be a sign that the underlying company isn't doing well. Maybe the stock has fallen over time, or sometimes high-risk companies have an IPO at low share prices to attract a broader range of investors. But low prices don't necessarily mean stocks are bad investments.
We asked three of our contributo... | We asked three of our contributors for their favorite low-price stocks, and Aurora Cannabis (NYSE: ACB), Snap (NYSE: SNAP), and TerraForm Power (NASDAQ: TERP) made the top of the list for very different reasons. Aurora Cannabis' acquisition strategy has put it in an enviable position, with opportunities to serve big ma... | We asked three of our contributors for their favorite low-price stocks, and Aurora Cannabis (NYSE: ACB), Snap (NYSE: SNAP), and TerraForm Power (NASDAQ: TERP) made the top of the list for very different reasons. Up more than 100% -- but still below its IPO price Leo Sun (Snap): Snap was once considered a doomed stock, ... | We asked three of our contributors for their favorite low-price stocks, and Aurora Cannabis (NYSE: ACB), Snap (NYSE: SNAP), and TerraForm Power (NASDAQ: TERP) made the top of the list for very different reasons. A cannabis company worth owning Todd Campbell (Aurora Cannabis): An aggressive M&A strategy that relied heav... | We asked three of our contributors for their favorite low-price stocks, and Aurora Cannabis (NYSE: ACB), Snap (NYSE: SNAP), and TerraForm Power (NASDAQ: TERP) made the top of the list for very different reasons. Up more than 100% -- but still below its IPO price Leo Sun (Snap): Snap was once considered a doomed stock, ... |
38378.0 | 2019-06-04 00:00:00 UTC | Cannabis Stocks Regaining Strength | ACB | https://www.nasdaq.com/articles/cannabis-stocks-regaining-strength-2019-06-04 | nan | nan | (RTTNews) - Shares of major cannabis companies are recovering from the extended losses they suffered on Monday following the U.S. Food and Drug Administration held its first-ever public hearing on cannabis and cannabidiol or CBD.
Shares of Tilray Inc. (TLRY) and Aurora Cannabis Inc. (ACB) are gaining more than 4 percen... | Shares of Tilray Inc. (TLRY) and Aurora Cannabis Inc. (ACB) are gaining more than 4 percent each, while those of Cronos Group Inc. (CRON) and Canopy Growth Corp. (CGC) are rising more than 3 percent each. According to acting FDA Commissioner Ned Sharpless, the regulator still does not know how safe the cannabis compoun... | Shares of Tilray Inc. (TLRY) and Aurora Cannabis Inc. (ACB) are gaining more than 4 percent each, while those of Cronos Group Inc. (CRON) and Canopy Growth Corp. (CGC) are rising more than 3 percent each. Friday's hearing is seen as just the first step in a process that could take years for the FDA to establish a legal... | Shares of Tilray Inc. (TLRY) and Aurora Cannabis Inc. (ACB) are gaining more than 4 percent each, while those of Cronos Group Inc. (CRON) and Canopy Growth Corp. (CGC) are rising more than 3 percent each. (RTTNews) - Shares of major cannabis companies are recovering from the extended losses they suffered on Monday foll... | Shares of Tilray Inc. (TLRY) and Aurora Cannabis Inc. (ACB) are gaining more than 4 percent each, while those of Cronos Group Inc. (CRON) and Canopy Growth Corp. (CGC) are rising more than 3 percent each. The FDA hearing did not result in any final decision, but it showed the conflicting views people had on the subject... |
38379.0 | 2019-06-04 00:00:00 UTC | Absent Immediate US Expansion Plans, Should You Buy Aurora Cannabis Stock Now? | ACB | https://www.nasdaq.com/articles/absent-immediate-us-expansion-plans-should-you-buy-aurora-cannabis-stock-now-2019-06-04 | nan | nan | Since listing on the New York Stock Exchange in October, Canada’s Aurora Cannabis (NYSE:) stock has rewarded investors richly. So far in 2019, ACB stock is up more than 60%. However, investors in the cannabis sector are also aware of how volatile the stock price of Aurora Cannabis and its peers can be.
On May 15, Auror... | On May 15, Aurora Cannabis released , which put a pressure on the price of ACB shares and other weed stocks, including Canopy Growth (NYSE:) and Tilray (NASDAQ:). As CBD oils rise in popularity, such a move would enable ACB to grow its brand among CBD-infused products and to reach a broader audience internationally. So... | On May 15, Aurora Cannabis released , which put a pressure on the price of ACB shares and other weed stocks, including Canopy Growth (NYSE:) and Tilray (NASDAQ:). Three Cons for Canopy Growth Stock Mixed Q3 Results: Despite 367% YoY revenue growth, ACB missed analyst estimates by a wide margin. So far in 2019, ACB stoc... | Three Pros for ACB Stock Cannabis Industry Leadership in Canada: As a leading cannabis producer, Aurora Cannabis is one of the top names in the Canadian market. If you are considering investing in Aurora Cannabis stock, a front-runner of the marijuana industry and especially the medical segment both in Canada and globa... | So far in 2019, ACB stock is up more than 60%. If you are considering investing in Aurora Cannabis stock, a front-runner of the marijuana industry and especially the medical segment both in Canada and globally, you may want to start building a position between the $6-$7 levels, and expect to hold ACB stock for several ... |
38380.0 | 2019-06-03 00:00:00 UTC | Why This Marijuana Stock Gained in May While Other Cannabis Stocks Cratered | ACB | https://www.nasdaq.com/articles/why-marijuana-stock-gained-may-while-other-cannabis-stocks-cratered-2019-06-04 | nan | nan | Stocks wilted in May. The S&P 500 plunged 6.4%, including dividends, which is a huge monthly drop that equates to an annualized loss of nearly 77%.
Last month was the market's first down month in 2019, and the worst May for stocks since 2010.
High-flying stocks were generally the hardest hit, particularly those in the ... | Shares of Canopy Growth, Aurora Cannabis (NYSE: ACB), Cronos Group, Tilray (NASDAQ: TLRY), and Aphria dropped 20.3%, 16.4%, 18%, 26%, and 13.6%, respectively. Along with making all-natural dried cheese snacks, the Canada-based company licenses, manufactures, and installs equipment for dehydrating organic materials, inc... | Shares of Canopy Growth, Aurora Cannabis (NYSE: ACB), Cronos Group, Tilray (NASDAQ: TLRY), and Aphria dropped 20.3%, 16.4%, 18%, 26%, and 13.6%, respectively. Along with making all-natural dried cheese snacks, the Canada-based company licenses, manufactures, and installs equipment for dehydrating organic materials, inc... | Shares of Canopy Growth, Aurora Cannabis (NYSE: ACB), Cronos Group, Tilray (NASDAQ: TLRY), and Aphria dropped 20.3%, 16.4%, 18%, 26%, and 13.6%, respectively. EnWave stock gains in May as cannabis stocks crater Cannabis stocks were largely dragged down by the poor overall market. Granted, shares of EnWave's fellow anci... | Shares of Canopy Growth, Aurora Cannabis (NYSE: ACB), Cronos Group, Tilray (NASDAQ: TLRY), and Aphria dropped 20.3%, 16.4%, 18%, 26%, and 13.6%, respectively. EnWave stock gains in May as cannabis stocks crater Cannabis stocks were largely dragged down by the poor overall market. This news naturally rattled the financi... |
38381.0 | 2019-06-02 00:00:00 UTC | 3 Marijuana Stocks That Wall Street Thinks You Should Buy | ACB | https://www.nasdaq.com/articles/3-marijuana-stocks-wall-street-thinks-you-should-buy-2019-06-02 | nan | nan | A couple of big Wall Street banks recently weighed in on a basket of widely traded marijuana stocks. Analysts at Jefferies and Bank of America agreed that two of the world's largest cannabis companies are good stocks to buy right now, but they disagreed sharply about a third licensed producer.
Blindly following recomme... | Analysts at Jefferies and Bank of America agreed that two of the world's largest cannabis companies are good stocks to buy right now, but they disagreed sharply about a third licensed producer. That's because consumer goods tend to compete for shelf space in mature markets, and HEXO's popular lineup should be able to r... | Aurora Cannabis: Derivative products on the way Analysts at Bank of America and Jefferies agree that Aurora Cannabis is a buy at recent prices. HEXO: Rising fast Back in February, Jefferies rated this Canadian licensed producer "underperform" because its joint partnership with Molson Coors Brewing (NYSE: TAP) doesn't s... | Analysts at Jefferies and Bank of America agreed that two of the world's largest cannabis companies are good stocks to buy right now, but they disagreed sharply about a third licensed producer. Aurora Cannabis: Derivative products on the way Analysts at Bank of America and Jefferies agree that Aurora Cannabis is a buy ... | Aurora Cannabis: Derivative products on the way Analysts at Bank of America and Jefferies agree that Aurora Cannabis is a buy at recent prices. This is a big reason Jefferies and Bank of America think this stock is a buy. The Motley Fool recommends Constellation Brands and HEXO. |
38382.0 | 2019-06-02 00:00:00 UTC | Is Aphria a Buy? | ACB | https://www.nasdaq.com/articles/aphria-buy-2019-06-02 | nan | nan | Canada's third largest pot producer, Aphria (NYSE: APHA), has turned into a battleground stock this year. While the company has started to attract a few ardent supporters on Wall Street, such as investment firm Jefferies, Aphria's shares remain woefully undervalued relative to its closest peers, Aurora Cannabis (NYSE: ... | While the company has started to attract a few ardent supporters on Wall Street, such as investment firm Jefferies, Aphria's shares remain woefully undervalued relative to its closest peers, Aurora Cannabis (NYSE: ACB) and Canopy Growth Corporation (NYSE: CGC). The company's image took a big hit late last year after so... | While the company has started to attract a few ardent supporters on Wall Street, such as investment firm Jefferies, Aphria's shares remain woefully undervalued relative to its closest peers, Aurora Cannabis (NYSE: ACB) and Canopy Growth Corporation (NYSE: CGC). Canada's third largest pot producer, Aphria (NYSE: APHA), ... | While the company has started to attract a few ardent supporters on Wall Street, such as investment firm Jefferies, Aphria's shares remain woefully undervalued relative to its closest peers, Aurora Cannabis (NYSE: ACB) and Canopy Growth Corporation (NYSE: CGC). Aphria's positives With a peak annual production capacity ... | While the company has started to attract a few ardent supporters on Wall Street, such as investment firm Jefferies, Aphria's shares remain woefully undervalued relative to its closest peers, Aurora Cannabis (NYSE: ACB) and Canopy Growth Corporation (NYSE: CGC). Should bargain hunters take advantage of Aphria's comparat... |
38383.0 | 2019-06-02 00:00:00 UTC | Ranking Canada's Top 10 Marijuana Growers | ACB | https://www.nasdaq.com/articles/ranking-canadas-top-10-marijuana-growers-2019-06-02 | nan | nan | Following decades of hiding in the shadows, marijuana now finds itself in the spotlight as one of the fastest-growing industries on the planet (especially in North America). Much of this has to do with Canada becoming the first industrialized country in the world to legalize recreational marijuana. According to Wall St... | Aurora Cannabis: Approximately 662,000 kilos As should be no surprise, Edmonton-based Aurora Cannabis (NYSE: ACB) has been the expected production leader for quite some time. Originally forecast for 195,000 kilos, much of which is expected to come from its 820,000-square-foot Valleyfield campus in Quebec, The Green Org... | Aurora Cannabis: Approximately 662,000 kilos As should be no surprise, Edmonton-based Aurora Cannabis (NYSE: ACB) has been the expected production leader for quite some time. Although the largest pot stock in the world hasn't divulged its annual peak production potential, it has let investors know that more than 4.4 mi... | Aurora Cannabis: Approximately 662,000 kilos As should be no surprise, Edmonton-based Aurora Cannabis (NYSE: ACB) has been the expected production leader for quite some time. Canopy Growth: 500,000 kilos to 550,000 kilos If there were a "Tier 1" of top growers, it's pretty much Aurora Cannabis and Canopy Growth (NYSE: ... | Aurora Cannabis: Approximately 662,000 kilos As should be no surprise, Edmonton-based Aurora Cannabis (NYSE: ACB) has been the expected production leader for quite some time. The first, Aphria One, is an organically constructed grow farm capable of 110,000 kilos of annual yield. 10 stocks we like better than Aurora Can... |
38384.0 | 2019-06-01 00:00:00 UTC | What's Next for Pot Stocks After Capacity Expansion? | ACB | https://www.nasdaq.com/articles/whats-next-pot-stocks-after-capacity-expansion-2019-06-01 | nan | nan | Last year featured a number of big changes for the marijuana industry. We witnessed Canada becoming the first industrialized country in the world to legalize recreational weed, had the U.S. Food and Drug Administration approve the first cannabis-derived drug, and witnessed multiple Canadian pot stocks uplist, or even g... | Meanwhile, Aurora Cannabis (NYSE: ACB) chose to pony up around $130 million to acquire Whistler Medical Marijuana in British Columbia earlier this year. Similarly, Atlantic-based OrganiGram Holdings (NASDAQ: OGI) announced an investment of 15 million Canadian dollars in a production line to make chocolate cannabis edib... | Meanwhile, Aurora Cannabis (NYSE: ACB) chose to pony up around $130 million to acquire Whistler Medical Marijuana in British Columbia earlier this year. Similarly, Atlantic-based OrganiGram Holdings (NASDAQ: OGI) announced an investment of 15 million Canadian dollars in a production line to make chocolate cannabis edib... | Meanwhile, Aurora Cannabis (NYSE: ACB) chose to pony up around $130 million to acquire Whistler Medical Marijuana in British Columbia earlier this year. To date, four growers have managed to land supply deals with all of Canada's provinces: Canopy Growth, Aphria (NYSE: APHA), CannTrust Holdings, and OrganiGram Holdings... | Meanwhile, Aurora Cannabis (NYSE: ACB) chose to pony up around $130 million to acquire Whistler Medical Marijuana in British Columbia earlier this year. While there's no concrete step-by-step guide to success in the weed industry, since there's never been any precedent of a legal pot industry before, there are a number... |
38385.0 | 2019-06-01 00:00:00 UTC | Is Cronos Group a Buy? | ACB | https://www.nasdaq.com/articles/cronos-group-buy-2019-06-01 | nan | nan | With adult-use marijuana being legalized in Canada seven months ago and with 33 states in the U.S. having legalized pot in some form, investors are seeing an industry worth tens of billions of dollars or more taking shape before their very eyes. In these early days, companies are mapping out their strategies for captur... | The two top producers, Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB) do get the highest valuations. Peace Naturals is an established brand, and Cronos has a joint venture with MedMen Enterprises (NASDAQOTH: MMNFF) to build a national retail chain of marijuana stores in Canada, giving the company a verticall... | The two top producers, Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB) do get the highest valuations. Today Cronos sells strain-specific cannabis oil into the Canadian medicinal marijuana market through its Peace Naturals brand. Cannabinoids from yeast In the long term, Cronos doesn't want to rely solely on d... | The two top producers, Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB) do get the highest valuations. To investors trying to understand marijuana stocks solely on the basis of production capacity, Cronos would seem to be lagging far behind its peers. MediPharm today has ability to produce the concentrates tha... | The two top producers, Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB) do get the highest valuations. A cannabinoid platform for derivative products In the long term, Cronos sees itself as a cannabinoid platform company. MediPharm Labs is a leading Canadian extraction company that purchases dried cannabis fro... |
38386.0 | 2019-05-31 00:00:00 UTC | Rising U.S.-China Tension Also Raises Profile of Aurora Cannabis Stock | ACB | https://www.nasdaq.com/articles/rising-u.s.-china-tension-also-raises-profile-aurora-cannabis-stock-2019-05-31 | nan | nan | If for whatever reason you’ve never heard of marijuana investments, your first look into the sector may be daunting. Initially, you’ll come across major names like Aurora Cannabis (NYSE:), which seemingly offers plenty of upside. But then you’ll find other names like Tilray (NASDAQ:) or Canopy Growth (NYSE:) and wonder... | But then you’ll find other names like Tilray (NASDAQ:) or Canopy Growth (NYSE:) and wonder: What separates ACB stock from the lookalike competition? Looming Economic Crisis Raises Profile of ACB Stock Everywhere I turn, I see evidence that the U.S.-China trade war is about to spiral intractably out of control. Of cours... | So how does the trade war benefit ACB stock? But then you’ll find other names like Tilray (NASDAQ:) or Canopy Growth (NYSE:) and wonder: What separates ACB stock from the lookalike competition? Of course, that narrative didn’t help ACB stock. | But then you’ll find other names like Tilray (NASDAQ:) or Canopy Growth (NYSE:) and wonder: What separates ACB stock from the lookalike competition? Of course, that narrative didn’t help ACB stock. Looming Economic Crisis Raises Profile of ACB Stock Everywhere I turn, I see evidence that the U.S.-China trade war is abo... | Of course, that narrative didn’t help ACB stock. But then you’ll find other names like Tilray (NASDAQ:) or Canopy Growth (NYSE:) and wonder: What separates ACB stock from the lookalike competition? Looming Economic Crisis Raises Profile of ACB Stock Everywhere I turn, I see evidence that the U.S.-China trade war is abo... |
38387.0 | 2019-05-31 00:00:00 UTC | 3 Great Reasons to Buy Aurora Cannabis Stock | ACB | https://www.nasdaq.com/articles/3-great-reasons-buy-aurora-cannabis-stock-2019-05-31 | nan | nan | If you're looking for a way to profit from the global marijuana boom, consider Aurora Cannabis (NYSE: ACB). The Canadian pot producer has built a leading position within the fast-growing cannabis industry, delivering jaw-dropping returns to investors along the way.
Better still, Aurora's stock is poised to deliver even... | If you're looking for a way to profit from the global marijuana boom, consider Aurora Cannabis (NYSE: ACB). And Canopy Growth (NYSE: CGC) Co-CEO Bruce Linton, perhaps unsurprisingly, has the most optimistic prediction of all: He believes cannabis could eventually disrupt markets totaling $500 billion. Constellation Bra... | If you're looking for a way to profit from the global marijuana boom, consider Aurora Cannabis (NYSE: ACB). The Canadian pot producer has built a leading position within the fast-growing cannabis industry, delivering jaw-dropping returns to investors along the way. This is perhaps one the reasons Aurora Cannabis has re... | If you're looking for a way to profit from the global marijuana boom, consider Aurora Cannabis (NYSE: ACB). Having built a formidable position in marijuana production, Aurora Cannabis stands to benefit more than perhaps any other company from this booming demand for cannabis. This is perhaps one the reasons Aurora Cann... | If you're looking for a way to profit from the global marijuana boom, consider Aurora Cannabis (NYSE: ACB). Among Aurora's rivals, only Canopy Growth can even claim 500,000 kilograms in peak production potential. As the largest marijuana producer, Aurora Cannabis will enjoy scale advantages over its smaller rivals. |
38388.0 | 2019-05-31 00:00:00 UTC | Investing in Marijuana Stocks: Everything You Need to Know | ACB | https://www.nasdaq.com/articles/investing-marijuana-stocks%3A-everything-you-need-know-2019-05-31 | nan | nan | The marijuana industry is expected to triple in the next five years ... and many investors are looking to profit.
As states and entire countries decriminalize or legalize cannabis and/or its components, there are loads of opportunities for entrepreneurs and existing companies.
But as in any nascent industry, there are ... | Evaluate the top marijuana stocks and exchange-traded funds (ETFs): Marijuana growers like Canopy Growth, Aurora Cannabis (NYSE: ACB), Tilray (NASDAQ: TLRY), and Aphria (NYSE: APHA). As states and entire countries decriminalize or legalize cannabis and/or its components, there are loads of opportunities for entrepreneu... | Evaluate the top marijuana stocks and exchange-traded funds (ETFs): Marijuana growers like Canopy Growth, Aurora Cannabis (NYSE: ACB), Tilray (NASDAQ: TLRY), and Aphria (NYSE: APHA). Understand the types of marijuana products There are two types of cannabis products: medical marijuana vs. recreational marijuana. Biotec... | Evaluate the top marijuana stocks and exchange-traded funds (ETFs): Marijuana growers like Canopy Growth, Aurora Cannabis (NYSE: ACB), Tilray (NASDAQ: TLRY), and Aphria (NYSE: APHA). Know what to look for in a marijuana stock Normal stock considerations, including: Management team Growth strategy Competitive position F... | Evaluate the top marijuana stocks and exchange-traded funds (ETFs): Marijuana growers like Canopy Growth, Aurora Cannabis (NYSE: ACB), Tilray (NASDAQ: TLRY), and Aphria (NYSE: APHA). Understand the risks of investing in marijuana stocks Legal and political risks Supply/demand imbalances Risk in those that are over-the-... |
38389.0 | 2019-05-30 00:00:00 UTC | A Completely Unknown Pot Stock Aims to Be Canada's Third-Largest Cannabis Grower | ACB | https://www.nasdaq.com/articles/completely-unknown-pot-stock-aims-be-canadas-third-largest-cannabis-grower-2019-05-30 | nan | nan | The marijuana landscape is transforming before our eyes. What had once been an industry that politicians swept under the rug is now considered mainstream throughout most of North America and Europe. Canada became the first industrialized country to legalize recreational weed this past October; Mexico stands ready to gi... | All eyes are on Canada's top cannabis growers Heading that industry are a number of familiar and popular names on Wall Street: Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). Canada became the first industrialized country to legalize recreational weed this past October; Mexico stands ready to give adult-use ... | All eyes are on Canada's top cannabis growers Heading that industry are a number of familiar and popular names on Wall Street: Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). Aurora Cannabis, the second-largest pot stock by market cap, projects as the largest producer by peak annual output. This assumes that... | All eyes are on Canada's top cannabis growers Heading that industry are a number of familiar and popular names on Wall Street: Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). Meanwhile, CannTrust's additional capacity of 100,000 kilos to 200,000 kilos of outdoor-grown marijuana will double or triple its prev... | All eyes are on Canada's top cannabis growers Heading that industry are a number of familiar and popular names on Wall Street: Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). 3 grower...or so we think. This unknown pot stock wants to become Canada's No. |
38390.0 | 2019-05-30 00:00:00 UTC | 4 CBD Stocks to Buy for Mainstream Marijuana Profits | ACB | https://www.nasdaq.com/articles/4-cbd-stocks-to-buy-for-mainstream-marijuana-profits-2019-05-30 | nan | nan | [Editor’s note: This story was previously published in March 2019. It has since been updated and republished.]
Traffic stats don’t lie: among investment categories, few have the draw of legal marijuana. And within this broad segment, companies specializing in cannabidiol, or CBD, have generated significant buzz. But wh... | Cowen Equity Research initiated coverage of ACB stock, rating it as “outperform,” and giving it a rich price-target premium. Aurora Cannabis (ACB) Source: Shutterstock Much of the enthusiasm towards Edmonton-based CBD (and THC) firm Aurora Cannabis (NYSE:) came off the back of an analyst upgrade. Analysts there view fa... | Aurora Cannabis (ACB) Source: Shutterstock Much of the enthusiasm towards Edmonton-based CBD (and THC) firm Aurora Cannabis (NYSE:) came off the back of an analyst upgrade. Cowen Equity Research initiated coverage of ACB stock, rating it as “outperform,” and giving it a rich price-target premium. Analysts there view fa... | Aurora Cannabis (ACB) Source: Shutterstock Much of the enthusiasm towards Edmonton-based CBD (and THC) firm Aurora Cannabis (NYSE:) came off the back of an analyst upgrade. Cowen Equity Research initiated coverage of ACB stock, rating it as “outperform,” and giving it a rich price-target premium. Analysts there view fa... | Aurora Cannabis (ACB) Source: Shutterstock Much of the enthusiasm towards Edmonton-based CBD (and THC) firm Aurora Cannabis (NYSE:) came off the back of an analyst upgrade. Cowen Equity Research initiated coverage of ACB stock, rating it as “outperform,” and giving it a rich price-target premium. Analysts there view fa... |
38391.0 | 2019-05-30 00:00:00 UTC | 5 Stocks Under $10 With Big Upside Potential | ACB | https://www.nasdaq.com/articles/5-stocks-under-%2410-with-big-upside-potential-2019-05-30 | nan | nan | Let’s start this article by stating that stocks under $10 aren’t necessarily cheap stocks. This is a common misconception. In the financial world, “cheap” is a valuation measure — a low price-to-earnings multiple, or low price-to-book ratio. Just because a stock is trading with a single-digit price tag, that doesn’t ne... | Aurora (ACB) Source: Shutterstock Price Tag Today: $8.30 The first stock on this list is an undervalued cannabis company with big upside potential in the event that the company shores up its balance sheet to compete with more well-funded peers. Yet, despite Aurora’s huge size, ACB stock is relatively undervalued. When ... | Aurora (ACB) Source: Shutterstock Price Tag Today: $8.30 The first stock on this list is an undervalued cannabis company with big upside potential in the event that the company shores up its balance sheet to compete with more well-funded peers. Yet, despite Aurora’s huge size, ACB stock is relatively undervalued. When ... | Aurora (ACB) Source: Shutterstock Price Tag Today: $8.30 The first stock on this list is an undervalued cannabis company with big upside potential in the event that the company shores up its balance sheet to compete with more well-funded peers. Yet, despite Aurora’s huge size, ACB stock is relatively undervalued. When ... | Aurora (ACB) Source: Shutterstock Price Tag Today: $8.30 The first stock on this list is an undervalued cannabis company with big upside potential in the event that the company shores up its balance sheet to compete with more well-funded peers. Yet, despite Aurora’s huge size, ACB stock is relatively undervalued. When ... |
38392.0 | 2019-05-29 00:00:00 UTC | Should You Buy Canopy Growth Stock Prior to Earnings in June? | ACB | https://www.nasdaq.com/articles/should-you-buy-canopy-growth-stock-prior-earnings-june-2019-05-29 | nan | nan | Since becoming listed at the New York Stock Exchange in May 2018, Canada-based Canopy Growth’s (NYSE:) stock has rewarded investors richly. So far in 2019, CGC stock is up almost 65%.
Source: Shutterstock
CGC is expected to . Now that the earnings season is fast approaching, let’s look at what may be next for the CGC s... | Three Cons for Canopy Growth Stock Mixed Results From Its Main Competitor: On May 15, Aurora Cannabis (NYSE:), one of the main competitors of Canopy Growth, released mixed earnings result, which initially sent down ACB and CGC shares as well as other weed stocks. Despite 367% year-over-year (YoY) growth in revenue, ACB... | Three Cons for Canopy Growth Stock Mixed Results From Its Main Competitor: On May 15, Aurora Cannabis (NYSE:), one of the main competitors of Canopy Growth, released mixed earnings result, which initially sent down ACB and CGC shares as well as other weed stocks. Despite 367% year-over-year (YoY) growth in revenue, ACB... | Three Cons for Canopy Growth Stock Mixed Results From Its Main Competitor: On May 15, Aurora Cannabis (NYSE:), one of the main competitors of Canopy Growth, released mixed earnings result, which initially sent down ACB and CGC shares as well as other weed stocks. Despite 367% year-over-year (YoY) growth in revenue, ACB... | Three Cons for Canopy Growth Stock Mixed Results From Its Main Competitor: On May 15, Aurora Cannabis (NYSE:), one of the main competitors of Canopy Growth, released mixed earnings result, which initially sent down ACB and CGC shares as well as other weed stocks. Despite 367% year-over-year (YoY) growth in revenue, ACB... |
38393.0 | 2019-05-29 00:00:00 UTC | Short Interest Is Surging for the Most Popular Pot Stock | ACB | https://www.nasdaq.com/articles/short-interest-surging-most-popular-pot-stock-2019-05-29 | nan | nan | Forget bitcoin -- marijuana remains the hottest viable investment opportunity on Wall Street. Rather than relying on intangible digital tokens, investors have witnessed the potential of the legal marijuana industry firsthand, which has been generating tens of billions of dollar a year in the black market for decades. W... | The buzz is strong with Aurora Cannabis Among the dozens of pot stocks for investors to choose from, none tends to be more popular than Aurora Cannabis (NYSE: ACB). Rather than relying on intangible digital tokens, investors have witnessed the potential of the legal marijuana industry firsthand, which has been generati... | The buzz is strong with Aurora Cannabis Among the dozens of pot stocks for investors to choose from, none tends to be more popular than Aurora Cannabis (NYSE: ACB). With Canada having legalized recreational weed in 2018, and new markets moving toward a legalized environment with each passing year, the legal cannabis en... | The buzz is strong with Aurora Cannabis Among the dozens of pot stocks for investors to choose from, none tends to be more popular than Aurora Cannabis (NYSE: ACB). Even though Aurora is only the second-largest marijuana stock by market cap, behind Canopy Growth, it has an avid group of supporters among the millennial ... | The buzz is strong with Aurora Cannabis Among the dozens of pot stocks for investors to choose from, none tends to be more popular than Aurora Cannabis (NYSE: ACB). Depending on your preferred source, the marijuana opportunity is huge. Inclusive of its home market of Canada, it has a production or distribution presence... |
38394.0 | 2019-05-29 00:00:00 UTC | Marijuana Player EnWave's Revenue Growth Accelerates to 110% | ACB | https://www.nasdaq.com/articles/marijuana-player-enwaves-revenue-growth-accelerates-110-2019-05-29 | nan | nan | EnWave (TSXV: ENW) (NASDAQOTH: NWVCF) reported second-quarter results for fiscal 2019 after the market close on Tuesday, May 28.
Revenue soared 110% year over year, which is an acceleration from growth of 73% last quarter and 103% in the fourth quarter of fiscal 2018. As with the last two quarters, earnings per share ... | Major cannabis market activity soon after the quarter ended In late April (fiscal third quarter), EnWave entered a licensing deal and formed an intellectual-property partnership with Aurora Cannabis (NYSE: ACB), a top Canadian marijuana grower. In the same month, EnWave and Tilray signed a royalty-bearing sublicense wi... | Major cannabis market activity soon after the quarter ended In late April (fiscal third quarter), EnWave entered a licensing deal and formed an intellectual-property partnership with Aurora Cannabis (NYSE: ACB), a top Canadian marijuana grower. In January, as I previously reported, "EnWave and its licensed cannabis par... | Major cannabis market activity soon after the quarter ended In late April (fiscal third quarter), EnWave entered a licensing deal and formed an intellectual-property partnership with Aurora Cannabis (NYSE: ACB), a top Canadian marijuana grower. In January, as I previously reported, "EnWave and its licensed cannabis par... | Major cannabis market activity soon after the quarter ended In late April (fiscal third quarter), EnWave entered a licensing deal and formed an intellectual-property partnership with Aurora Cannabis (NYSE: ACB), a top Canadian marijuana grower. As with the last two quarters, earnings per share came in at breakeven. Wha... |
38395.0 | 2019-05-29 00:00:00 UTC | Aphria Stock Very Well May Have 74% Upside Potential | ACB | https://www.nasdaq.com/articles/aphria-stock-very-well-may-have-74-upside-potential-2019-05-29 | nan | nan | With a $1.6 billion market cap, Aphria (NYSE:) does not get the type of coverage that many cannabis stocks get. But just because a company isn’t the largest doesn’t mean it should be discarded. Is this the case for Aphria stock?
Source: Shutterstock
It could be, but with such a young industry at hand, there are numerou... | Of the all the stocks above — CGC, ACB, NBEV, CRON — and including Tilray (NASDAQ:), Aphria stock had the third highest revenue figure for the quarter. Multi-billion dollar investments along with collaborations and discussions with prominent and well-known companies have helped these names rise to the top of the cannab... | Of the all the stocks above — CGC, ACB, NBEV, CRON — and including Tilray (NASDAQ:), Aphria stock had the third highest revenue figure for the quarter. With a $1.6 billion market cap, Aphria (NYSE:) does not get the type of coverage that many cannabis stocks get. Later in April, Aphria completed a $300 million converti... | Of the all the stocks above — CGC, ACB, NBEV, CRON — and including Tilray (NASDAQ:), Aphria stock had the third highest revenue figure for the quarter. With a $1.6 billion market cap, Aphria (NYSE:) does not get the type of coverage that many cannabis stocks get. A Closer Look at Aphria Stock Last month, Aphria . | Of the all the stocks above — CGC, ACB, NBEV, CRON — and including Tilray (NASDAQ:), Aphria stock had the third highest revenue figure for the quarter. Will Aphria stock do the same? That’s underscored by Aphria’s current assets falling more than 26% from $418 million to just $308.5 million in six months. |
38396.0 | 2019-05-29 00:00:00 UTC | Aphria Has Big-League Potential In Early Innings Of Cannabis Stocks Game | ACB | https://www.nasdaq.com/articles/aphria-has-big-league-potential-in-early-innings-of-cannabis-stocks-game | nan | nan | The legal cannabis industry is still in the early innings of growth and as such, it is fragmented, fraught with risk and also chock full of potentially compelling growth stories. As legal marijuana is still a nascent business, many of the largest companies in this space are not that large at all, by broader market stan... | Meanwhile, Aphria (NYSE:) is even further down the roster, with a market capitalization of just $1.82 billion as of yesterday, putting the shares of the Canadian medical marijuana firm squarely in small-cap territory. With that permit, the company “stands as the only licensed producer in Germany with the permission to ... | Source: Shutterstock Aurora Cannabis (NYSE:) and Canopy Growth (NYSE:CGC) are two of the largest marijuana companies trading on major U.S. exchanges, but those stocks have a combined market value less than $19 billion. Interim CEO Irwin Simon, the founder and former CEO of Hain Celestial (NASDAQ:), is making his mark o... | Source: Shutterstock Aurora Cannabis (NYSE:) and Canopy Growth (NYSE:CGC) are two of the largest marijuana companies trading on major U.S. exchanges, but those stocks have a combined market value less than $19 billion. “Comparing forecasts for Canada’s big pot companies in 2020, Canopy Growth stock trades for almost 80... | Source: Shutterstock Aurora Cannabis (NYSE:) and Canopy Growth (NYSE:CGC) are two of the largest marijuana companies trading on major U.S. exchanges, but those stocks have a combined market value less than $19 billion. Indeed, Aphria stock has the makings of a small-cap growth story and recent price action in the share... |
38397.0 | 2019-05-28 00:00:00 UTC | 3 Stocks Poised for Huge Growth Over the Next Decade | ACB | https://www.nasdaq.com/articles/3-stocks-poised-huge-growth-over-next-decade-2019-05-29 | nan | nan | No matter how far the S&P 500 runs, some stocks hold such massive growth potential that they'd be too compelling to pass up even at current prices. Because for a growth stock, what seems overvalued today would still appear cheap if you looked back some years later. You just wouldn't want to miss out on those years of m... | Here's why premium cooler manufacturer Yeti (NYSE: YETI), financial payments processor Visa (NYSE: V), and marijuana producer Aurora Cannabis (NYSE: ACB) made the cut. Of course, Yeti has yet to announce any such lens-widening initiatives, but the GoBox suggests it has those ideas in mind, and investors may want to mak... | Here's why premium cooler manufacturer Yeti (NYSE: YETI), financial payments processor Visa (NYSE: V), and marijuana producer Aurora Cannabis (NYSE: ACB) made the cut. One can safely expect Visa's card base and revenue to rise as the world's banked population expands and e-commerce grows, both of which should boost dem... | Here's why premium cooler manufacturer Yeti (NYSE: YETI), financial payments processor Visa (NYSE: V), and marijuana producer Aurora Cannabis (NYSE: ACB) made the cut. Time to invest in this megatrend Neha Chamaria (Visa): With technological advancement, more nations across the globe are realizing the role of financial... | Here's why premium cooler manufacturer Yeti (NYSE: YETI), financial payments processor Visa (NYSE: V), and marijuana producer Aurora Cannabis (NYSE: ACB) made the cut. The GoBox is an exceptionally durable gear storage box, much like its coolers are certified bear-proof (yes, there is such a thing). All Visa does is pr... |
38398.0 | 2019-05-28 00:00:00 UTC | Aurora Cannabis Stock Starts To Distinguish Itself From The Pot-Stock Pack | ACB | https://www.nasdaq.com/articles/aurora-cannabis-stock-starts-distinguish-itself-pot-stock-pack-2019-05-28 | nan | nan | With nothing more than a passing glance, marijuana company Aurora Cannabis (NYSE:) doesn’t look terribly different than peers and rivals, like Tilray (NASDAQ:) or Canopy Growth (NYSE:). Cannabis is cannabis. A closer, second look at the company, however, makes clear that an investment in ACB stock is considerably diffe... | A closer, second look at the company, however, makes clear that an investment in ACB stock is considerably different than an investment in other marijuana stocks. Also noteworthy is the fact that 10% of ACB’s last quarter’s business was driven by sales of services and products, rather than cannabis itself. Passing … Fo... | Passing … For Now Yet, as much as what the company does to differentiate itself, some owners of ACB stock have expressed concern over what the cannabis company doesn’t appear interested in doing. A closer, second look at the company, however, makes clear that an investment in ACB stock is considerably different than an... | A closer, second look at the company, however, makes clear that an investment in ACB stock is considerably different than an investment in other marijuana stocks. Also noteworthy is the fact that 10% of ACB’s last quarter’s business was driven by sales of services and products, rather than cannabis itself. Passing … Fo... | Passing … For Now Yet, as much as what the company does to differentiate itself, some owners of ACB stock have expressed concern over what the cannabis company doesn’t appear interested in doing. A closer, second look at the company, however, makes clear that an investment in ACB stock is considerably different than an... |
38399.0 | 2019-05-27 00:00:00 UTC | Cronos Group Could Be the Bargain of a Lifetime | ACB | https://www.nasdaq.com/articles/cronos-group-could-be-bargain-lifetime-2019-05-27 | nan | nan | Cronos Group (NASDAQ: CRON), Canada's third-largest pot company by market capitalization, has suddenly turned into a black sheep. In effect, the company's shares have shed 24% of their value since hitting a high-water mark last March following the closure of its $1.8 billion deal with Malboro-maker Altria (NYSE: MO).
... | Wall Street has thus shown a clear preference of late for companies with elite production outputs such as Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). The reason being is that higher production capacities allow companies to meet the demand of the high-volume recreational space, while also enabling the exp... | Wall Street has thus shown a clear preference of late for companies with elite production outputs such as Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). Cronos Group (NASDAQ: CRON), Canada's third-largest pot company by market capitalization, has suddenly turned into a black sheep. A supply chain moat Altri... | Wall Street has thus shown a clear preference of late for companies with elite production outputs such as Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). Now, on the mass market side of the equation, Altria and Cronos are probably going to turn to contract farmers to quickly ratchet up production following t... | Wall Street has thus shown a clear preference of late for companies with elite production outputs such as Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC). Here's what investors might be missing about this underappreciated pot stock. Canada's top cannabis companies, in kind, have largely turned their attention... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.